

# CURRICULUM VITAE

December 3, 2025

## Personal Information: Matthew Edward Nielsen

### Business Address:

Department of Urology  
University of North Carolina at Chapel Hill School of Medicine  
2107 Houpt Physicians Office Building, Campus Box 7235  
170 Manning Drive  
Chapel Hill, NC 27599-7235  
Phone: 919.966.2574  
Fax: 919.966.0098  
Email: [mnielsen@med.unc.edu](mailto:mnielsen@med.unc.edu)  
Twitter / X: @m\_e\_nielsen

### Address of Clinical Investigation:

UNC Hospitals  
The University of North Carolina at Chapel Hill  
101 Manning Drive  
Chapel Hill, NC 27599-7600

## Education and Training:

- |           |   |
|-----------|---|
| 2019      | Advanced Training Program in Healthcare Delivery Improvement<br>(Accelerated version)<br>Intermountain Healthcare Delivery Institute<br>Murray, Utah  |
| 2015-2017 | Postdoctoral Fellow<br>Mentored Training in Dissemination and Implementation Research in<br>Cancer (MT-DIRC; NCI Grant 1 R25 CA171994-01A1)<br>Washington University<br>St. Louis, Missouri |
| 2010-2012 | Master's of Science, Clinical Research<br>Department of Epidemiology<br>University of North Carolina Gillings School of Global Public Health<br>Chapel Hill, North Carolina                 |
| 2003-2008 | Resident, Brady Urological Institute<br>The Johns Hopkins Hospital<br>Baltimore, Maryland   |

2002-2003	Intern, Department of Surgery The Johns Hopkins Hospital Baltimore, Maryland
1998-2002	M.D. The Johns Hopkins University School of Medicine Baltimore, Maryland
1993-1998	B.A., with Distinction American Studies—Emphasis in Health Policy and Law University of Kansas Lawrence, Kansas

## Professional Experience

### Academic Appointments

2021-present	John Sloan Rhodes and John Flint Rhodes Distinguished Professor
2020-present	Chair
2020-present	Professor with Tenure
2015-2020	Associate Professor with Tenure
2013-2015	Assistant Professor Department of Urology UNC Chapel Hill School of Medicine Chapel Hill, North Carolina
2025-present	Adjunct Professor
2015-2025	Adjunct Associate Professor
2012-2015	Adjunct Assistant Professor Department of Epidemiology UNC Chapel Hill Gillings School of Global Public Health Chapel Hill, North Carolina
2025-present	Adjunct Professor
2019-2025	Adjunct Associate Professor
2014-2019	Adjunct Assistant Professor Department of Health Policy and Management UNC Chapel Hill Gillings School of Global Public Health Chapel Hill, North Carolina
2009-2013	Assistant Professor Department of Surgery, Division of Urology UNC Chapel Hill School of Medicine Chapel Hill, North Carolina

06/08-12/08    Instructor  
James Buchanan Brady Urological Institute  
Johns Hopkins Medical Institutions  
Baltimore, Maryland

**Additional Appointments—Extramural**

2025-present    Learning Health Systems Strategy Leadership Consortium  
2024-2025        Scholar in Diagnostic Excellence  
National Academy of Medicine  
Washington, DC

2022-present    Chair, Science and Quality Council  
2019-2022        Chair, Quality Improvement and Patient Safety Committee  
American Urological Association  
Linthicum, Maryland

2014-present    Clinical Investigator  
Kaiser Permanente Center for Health Research  
Health Care Systems Research Network  
Kaiser Permanente Northwest  
Portland, Oregon

2025-present    Consultant Urologist, Prostate Cancer and Health Equity, Population  
Health and Medical Science Committee

2013-2017        Consultant Urologist, High Value Care Task Force  
American College of Physicians  
Philadelphia, Pennsylvania

**Additional Appointments—Intramural**

2021-2025        Director of Quality  
UNC Faculty Physicians  
UNC School of Medicine

2018-2021        Associate Director  
2014-present     Core Faculty Member  
Institute for Healthcare Quality Improvement  
UNC Health Care System  
Chapel Hill, North Carolina

2013-2018        Director, Division of Urologic Oncology  
Department of Urology  
UNC Chapel Hill School of Medicine

Chapel Hill, North Carolina

- 2017-2021      Physician Lead for Surgical Services  
Opioid Stewardship Initiative  
UNC Health Care System  
Chapel Hill, North Carolina
- 2009-2020      Physician Service Line Leader for Urology  
Inpatient Patient Safety and Quality Improvement Program  
UNC Memorial Hospital  
Chapel Hill, North Carolina
- 2009-present    Research Fellow  
Cecil G. Sheps Center for Health Services Research  
UNC Chapel Hill  
Chapel Hill, North Carolina
- 2009-present    Clinical Research Program Member  
Lineberger Comprehensive Cancer Center  
UNC Chapel Hill School of Medicine  
Chapel Hill, North Carolina

### **Honors and Awards**

- H. Fleming Fuller Award, UNC Health Care, 2022
- Young Urologist of the Year, American Urological Association Young Urologists Committee, 2018
- Castle Connolly Top Doctors, 2017-2026
- UNC Health Care Medical Friend of Nursing Award, 2017
- Elected by peers for inclusion in Best Doctors in America®, 2013-2021
- North Carolina's Best Doctors, *Business North Carolina* magazine, 2012-2024
- UNC Faculty Physicians Award for Carolina Care Excellence [top quartile nationally of Clinician and Group Consumer Assessment in Healthcare Providers and Systems (CG-CAHPS) survey], 2016-2018, 2024
- Vitals.com Patients' Choice and Compassionate Doctor Awards, 2015
- Urology Care Foundation / Astellas Rising Stars in Urology Research Award, 2013-2016

- Mentor for Surgical Outcomes Club Zinner Health Services Research Fellowship, 2015-16
- Best Video, BJU International Social Media Awards, 2015
- Urology Attending of the Year, presented by the UNC Department of Urology Residents, 2014
- American College of Surgeons Mentorship Program, 2013-14
- Who's Who in North American Education, 2012-13
- American Urological Association Leadership Program, 2012-13
- National Institutes of Health Loan Repayment Program, Competing Renewal 2012-2015
- Best Reviewer, Bladder and Kidney Cancer, *Journal of Urology*, 2012
- Fellow, American College of Surgeons, 2012
- Best Poster, Superficial bladder cancer moderated poster session II, 2012, American Urological Association National Meeting
- National Institutes of Health Loan Repayment Program Award, 2010-2012
- 3<sup>rd</sup> Prize, AUA / Gyrus ACMI Clinical Research Essay Contest, 2008, American Urological Association National Meeting
- American Society for Clinical Oncology (ASCO) Merit Award, 2007
- 1<sup>st</sup> Prize Podium Presentation, The Maryland Urological Meeting, Baltimore, Maryland, 2007
- 2<sup>nd</sup> Prize, Pfizer Resident Clinical Research Essay Competition, 2006, Mid-Atlantic Section of the American Urological Association
- Alpha Omega Alpha, 2002, Johns Hopkins University School of Medicine
- Student Research Scholar, 2001, American Foundation for Urologic Diseases
- Harold Lamport Medical Student Research Prize, 2001, Johns Hopkins University School of Medicine
- Phi Beta Kappa, 1998, University of Kansas

- J. Michael Young Undergraduate Research Award, 1997, University of Kansas Honors Program
- Summerfield Scholarship for Excellence in Biomedical Sciences, 1996, University of Kansas
- Kansas Health Institute Health Policy and Law Summer Scholar, 1996

## PROFESSIONAL SERVICE

### International Activities

- International Steering Committee, Transurethral Resection and Single instillation intravesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT) Improvement Study. British Urology Registrars in Surgical Training (BURST) Collaborative, 2020-2023
- United States National Coordinator, IDENTIFY (The Investigation and Detection of urological Neoplasia in paTients referred for suspected urinary tract cancer: a multicenter anaLYsis) Study. British Urology Researchers in Surgical Training (BURST), 2018-2021
- High Value Practice Alliance (hvpaa.org), 2017-present
  - Co-Director, National Dissemination of Opioid Stewardship (partnership with American Hospital Association), 2019-2023
  - Co-Director, Cross-Institutional Quality Improvement Implementation Committee, 2018-2022
  - UNC School of Medicine Faculty Representative, 2017-2020
- Member, Writing Committee, International Society of Geriatric Oncology (SIOG) Task Force on the Treatment of Bladder Cancer in Older Adults, 2016-2020

### National Activities

- United States Preventive Services Task Force, Invited expert reviewer for *Screening for Prostate Cancer: A Systematic Review*, 2025
- National Academy of Medicine
  - Learning Health Systems Strategy Leadership Consortium, 2025-present
  - Scholars in Diagnostic Excellence, 2024-2025
- National Quality Forum Diagnostic Excellence Committee, 2023-2025
- Council of Medical Specialty Societies

- Encoding Equity in Clinical Research and Practice Alliance Clinical / Specialty Societies Task Force, 2024-present
- Reconsidering Race in Clinical Algorithms: Driving Equity through New Models in Research and Implementation (Invited Participant). National Academy of Medicine, June 27, 2023
- Registry Science and Research Initiative Workgroup, 2022-present
  
- American College of Physicians
  - Consultant Urologist, Prostate Cancer and Health Equity, Population Health and Medical Science Committee, 2025-present
  - Performance Measurement Committee, 2018-2020
  - Consultant Urologist, High Value Care Task Force, 2013-2017
  
- American Urological Association
  - Chair, Science and Quality Council, 2022-present
  - Chair, Quality Improvement and Patient Safety Committee, 2019-2022
  - Member, Quality Improvement and Patient Safety Committee, 2013-2019
  - Ex Officio member, AUA Practice Guidelines Committee, 2019-present
  - Ex Officio member, AUA Data Committee, 2019-present
  - AUA Microhematuria Guideline Panel Member, 2018-2020
  - Chair, 2017 Quality Improvement Summit, Challenges and Opportunities for Stewardship of Urological Imaging
  - External Reviewer, AUA Clinical Practice Guidelines, 2012-2019
  - Regulatory Working Group, 2017-2021
  - AQUA Qualified Clinical Data Registry Executive Workgroup, 2015-present
  - Electronic Medical Records Decision Support and Telemedicine Integration Working Group, 2014-2019
  - AUA Representative, Physicians' Electronic Health Record Consortium, 2014-2018
  - AUA Representative, Alliance of Specialty Medicine Physician Policy Roundtable on Accountable Care Organizations and Alternative Payment Models, Washington, DC, October 31, 2013
  - AUA Leadership Program, 2012-2013
  
- U.S. News & World Report Medical Editorial Review Board, 2021-present
  
- Centers for Medicare and Medicaid Services
  - Technical Expert Panel, CMS Quality Measure Development Plan (MDP) and Quality Measure Index (QMI), 2019-2022
  - Technical Expert Panel, "Defining and Rewarding Computed Tomography Quality and Safety" Quality Measure Development, 2018-2021

- National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) Registry Bladder Cancer Workgroup, 2015-2023
- Association of Women Surgeons
  - Coaching Program, 2020-2021
  - #HeForShe Committee, 2019-2022
- Michigan Urological Surgery Improvement Collaborative (MUSIC)
  - Outdoor MUSIC QI collaborative, 2022-present
  - External Peer Reviewer, Videos to Identify Developmental and Educational Opportunities (VIDEO) radical prostatectomy project, 2018-2022
- Physician Consortium for Performance Improvement (PCPI), 2013-2019
  - Representative from the Council for Medical Specialty Societies (CMSS), 2015-2019
  - Member, Outcomes Ad Hoc Committee, 2013-2015
- Bladder Cancer Advocacy Network (BCAN), 2009-2017
  - Chair, Think Tank Planning Committee, 2016-2017
  - Co-Chair, Think Tank Planning Committee, 2015-2016
  - Annual Think Tank Steering Committee, 2013-2017
  - Patient Centered Outcomes and Policy Working Group, 2012-2017
  - Non-muscle-invasive bladder cancer working group, 2009-2012
  - Scientific Advisory Board Member, 2009-2017
- Quality in Patient Care Subcommittee, American College of Surgeons Committee on Surgical Palliative Care. 2014-2022
- External Advisory Board, University of Michigan Dow Division of Urological Health Services Research HSR Symposium, 2016
- Society for Medical Decision Making, Membership Committee, 2013-2015
- Genitourinary Surgery Subcommittee, Cancer and Leukemia Group B (CALGB), 2009-2011

### **Regional Activities**

- Physician Advisory Panel for Oncology Alternative Payment Model, Blue Cross Blue Shield of North Carolina, 2019-2021
- North Carolina Advisory Committee on Cancer Control and Coordination (appointed by Governor Roy Cooper), 2018-2021

- North Carolina Hospital Association Coalition for Model Opioid Practices, Prevention Workgroup, 2017-2020
- American Urological Association Southeastern Section, Board of Directors, North Carolina Alternate Representative, 2013-2020
- Medical Advisor and co-Founder, Triangle Bladder Cancer Support Group (monthly), Chapel Hill, North Carolina, September 2010-2021
- Urology Physician Advisory Panel for Specialty Tiering Product, Blue Cross Blue Shield of North Carolina, 2019
- Co-Chair, North Carolina Kidney Cancer Association Patient Forum, Chapel Hill, NC, December 12, 2015
- Medical Advisor, Prostate Cancer Coalition of North Carolina, 2009-2013
- North Carolina Oncology Association, At-Large Executive Board Member, 2010-2012
- Program Planning Committee Member, North Carolina Oncology Association Membership Meeting, August 12-13, 2011.
- Faculty Chair, Bladder Cancer Advocacy Network Patient Forum, Chapel Hill, North Carolina, May 15, 2010.

### **Institutional Activities**

- Board of Managers, UNC Health Alliance and UNC Senior Alliance, 2024-present
- Quality Improvement Oversight Committee Advisory Group, UNC Health System, 2024-present
- UNC Health Care System Forward Together 2030 Strategic Plan Initiative,
  - Physician Lead for “Strengthening Core” Pillar, 2023
  - Clinical Excellence Vertical Owner, 2024-present
- UNC Medical Center Integrated Planning Team, Physician Executive Lead for Quality and Safety, 2022-2024
- UNC Health Care System Enterprise Risk Management, Physician Executive Sponsor for Radiological Incidental Findings Improvement Initiative, 2021-2024
- UNC Faculty Physicians

- Advanced Practice Provider Steering Committee, 2022-present
  - Executive Team, Director of Quality and Patient Safety, 2021-present
  - Clinical Department Chairs' Liaison to the UNC Medical Center Improvement Council, 2021-present
  - Executive Committee, 2021-present
  - Compensation Committee, 2021-2024
  - Clinical Chair Representative, UNC School of Medicine Nominating Committee, 2021-2024
- UNC Lineberger Comprehensive Cancer Center Team Science Initiative Working Group, 2021-2023
- Surgical Services Physician Lead, Blood Product Optimization Program, UNC Health Care System Care Redesign Initiative, 2020-2023
- UNC Health COVID Vaccine Implementation Team, UNC Faculty Practice Chair Representative, 2020-2021
- Dean's Advisory Committee, UNC School of Medicine, 2020-present
- UNC Hospitals Medical Staff Executive Committee, 2020-present
- UNC School of Medicine COVID Surge Planning Provider Redeployment Core Team, March-July 2020
- Associate Director, Institute for Healthcare Quality Improvement, UNC Health Care System, 2018-2021
- Cancer Care Quality and Value Council, UNC Health Care System, 2018-2022
- Surgical Services Physician Lead, Systemwide Opioid Stewardship Project, UNC Health Care System, 2018-2021
- Professionalism and Patient Complaint Monitoring Committee, UNC Health Care System, 2018-2021
- Physician Faculty, UNC Health Care System Improvement Leaders Program, 2018-2020
- Performance Metrics and Quality Committee Member, UNC Health Alliance, 2016-2024
- Physician Executive Sponsor, Catheter-associated Urinary Tract Infection (CAUTI) Improvement Initiative, UNC Health Care System, 2015-2019

*27% reduction in CAUTI from CY2015-CY2016 (exceeded target of 5% reduction; 1.52 CAUTI / 1000 catheter-days)*

- Survivorship Program Advisory Board Member, UNC Lineberger Comprehensive Cancer Center, 2014-2020
- Wound, Ostomy, and Continence Committee; Surgical Services, UNC Health Care System, 2013-2019
- Medical Student Career Goals Advisor for Urology, UNC School of Medicine, 2012-present
- Physician Service Leader for Institutional Performance Improvement (weekly), UNC Urology service, 2009-2021
- Five-year Review Committee, Anesthesia Department Chair, UNC School of Medicine, 2018
- Physician Advisor for Clinical Documentation Integrity Project, UNC Health Care System Surgical Services, (weekly) 2012-2018
- Alpha Omega Alpha Honor Medical Society Admissions Committee member, UNC Chapel Hill School of Medicine, 2013-2016
- Integrated Cancer Information and Surveillance System (ICISS) Steering Committee, Carolina Cancer Outcomes Research Program, UNC Lineberger Comprehensive Cancer Center, 2013-2016
- EPIC Electronic Medical Record Transition Physician Advisory Council, UNC Health Care System, 2013-2014
- ICD-10 Implementation Task Force Leadership Team, UNC Health Care System, 2013-14
- Peer Review Committee, UNC Department of Surgery 2011-2013
- Oncology Protocol Review Committee, Lineberger Comprehensive Cancer Center, UNC Chapel Hill School of Medicine, 2009-2016
- Judge, Graduate student poster contest, Translational Medicine Symposium, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, April 17, 2013
- Project Leader for Urology Medical Student Recruitment, Education and Curriculum Development Initiative, supported by the Lester Persky Endowment for Urology Research, Johns Hopkins Hospital, 2006-2008

- Resident Representative for Urology Department Faculty Meeting, Johns Hopkins Hospital, 2006-2008
- Urology Department Project Leader for Electronic Provider Order Entry (POE) implementation, Johns Hopkins Hospital, 2006
- Urology Department Representative, Johns Hopkins Hospital House Staff Council, 2005-2006
- Resident Representative, Johns Hopkins Hospital Radiation Oncology Internal Program Review, 2005
- Student Representative, Johns Hopkins University School of Medicine Admissions Committee, 2001-2002

## BIBLIOGRAPHY

[\*asterisk denotes mentee first author (resident/fellow/graduate student/junior faculty)]

### Clinical Guidelines:

1. Barocas DA, Boorjian SA, Alvarez RD, Downs TM, Gross CP, Hamilton BD, Kobashi KC, Lipman RR, Lotan Y, Ng CK, **Nielsen ME**, Peterson AC, Raman JD, Smith-Bindman R, and Souter LH (2020). Microhematuria: American Urological Association Guideline. *J Urol*, 204(4): 778-786. PMID: 32698717
2. Mottet N, Ribal MJ, Boyle H, De Santis M, Caillet P, Choudhury A, Garg T, **Nielsen M**, Wuthrich P, Gust KM, Shariat SF, Gakis G, and Jocaille L (2020). Management of bladder cancer in older patients: position paper of a SIOG task force. *J Geriatric Oncology* 11(7): 1043-1053 PMID 32057720
3. **Nielsen ME**, Qaseem A; High Value Care Task Force of the American College of Physicians (2016). Hematuria as a marker of occult urinary tract malignancy: Advice for High Value Care from the American College of Physicians. *Annals Int Med.* 164(7): 488-97. PMID: 26810935

### Peer-Reviewed Original Research

Scopus Author ID: 9234222100 | ORCID 0000-0002-7853-9095

H-index 43, i10-index 64 | Total citations 6790 (via Google Scholar <http://ow.ly/oVWt30rsjfb> 11/2025)

1. Maeng D, Holcomb M, **Nielsen ME**, Popek S, Garg T, Aka AA, Grant M, Hoffman RL, Hesham WM, Sun V, Sticca RP, and Krouse R (2025). Impact of ostomy self-management telehealth training for rural cancer survivors on healthcare utilization and economic outcomes in the United States. *J Rural Health*, in press. 18 typed pages.

2. Gessner KH, Deal AM, Feinberg A, Myers S, Poulos K, Heiling H, Wobker S, Akella P, Bjurlin MA, Commander C, Milowsky M, **Nielsen ME**, Raynor MC, Smith AB, Wallen EM, Johnson DC, Kim WY, and Tan HJ (2025). Impact of renal mass biopsy on decision-making experience for clinical T1 renal masses. *J Urol*; Online ahead of print. PMID 41151063
3. Desai AP, Carpinito G, Feinberg A, Meza Jarquin MA, Zipple I, Usinger D, Myers S, Basak R, Wallen E, Bjurlin MA, Raynor M, **Nielsen ME**, Tan HJ (2025). Data sources for clinical T1 renal masses and the potential for bias. *Clinical Genitourinary Cancer*; 23(6): 102435. PMID 41072239
4. Spratte BN, Poulos K, Reines K, Blalock S, Bennett AV, Gessner KH, **Nielsen ME**, Reuland DS, Basch E, and Tan HJ (2025). Surgeon decision-making: A contemporary, qualitative analysis of urologists. *J Am Coll Surg* Online ahead of print PMID 40680091
5. Nazzal EM, Deal AM, Borgert B, Heiling H, Bennett AV, Blalock S, Meeks W, Fang R, Teal R, Vu MB, Gotz D, **Nielsen ME**, Harris AHS, Basch E, and Tan HJ (2025). Use and usefulness of risk prediction tools in urologic surgery: Current state and path forward. *Urol Pract* Online ahead of print PMID 40067913
6. Khadhour S, et al. [IDENTIFY Study Group: **Nielsen ME** among Pubmed indexed collaborator authors] (2025). The significance of isolated de novo red patches in the bladder in patients referred with suspected urinary tract cancer: Results from the IDENTIFY study. *BJUI Compass*, 6(1):e475. PMID 39877557
7. Knowlton S, Wardell AC, Smith A, Bjurlin M, **Nielsen M**, and Tan HJ (2025). Association of pre-cystectomy pathway in patients with bladder cancer on post-operative outcomes. *Clinical Genitourinary Cancer*. 23(2): 102297. PMID 39847909
8. Gessner KH\*, Preisser JS, Pfaff E, Wang R, Walters K, Bradford R, Clark M, Ehlers, M, and **Nielsen ME** (2025). Predictors of new persistent opioid use after surgery in adults. *Anesthesiology and Perioperative Science* 3(1):2 PMID 40051586.
9. Garg T\*, Frank K, Cohen HJ, Johns AM, Maheswari C, McMullen C, **Nielsen ME**, Murphy T, Rabinowitz K, Miller H, Kirchner, and Murphy T (2024). “Faith and a Sunny Day”: Association of patient frailty with strain experienced by informal caregivers of older adults with non-muscle-invasive bladder cancer. *J Geriatric Oncol* 15(8):102060 PMID 39244892
10. Oh NL, Frisbie J, Li L, Brown C, **Nielsen ME**, Scales CD Jr, Domino ME, and Friedlander DF\* (2024). Preoperative care intensity and cost for renal colic: Implications for surgical value-based reforms. *Urol Practice* 12(1): 104-113 PMID 39356578
11. Xu J\*, Ma C, Hirschey R, Liu J, Neidre DB, **Nielsen ME**, Keyserling TC, Tam, X, and Song L (2024). Associations of role, area deprivation index, and race with health behaviors and

- body mass index among localized prostate cancer patients and their partners. *J Cancer Survivorship*, Online ahead of print PMID 38888710
12. Tan HJ, Spratte BN, Deal AM, Heiling HM, Nazzal EM, Meeks W, Fang R, Teal R, Vu MB, Bennett AV, Blalock S, Chung AE, Gotz D, **Nielsen ME**, Reuland DS, Harris AS, and Basch E (2024). Clinical Decision Support in Surgery: A Mixed Methods Study on Design and Implementation Perspectives from Urologists. *Urology* 190: 15-23. PMID 38697362
  13. Ippolito GM, Reines K, Meeks WD, Mbassa R, Ellimootil C, Faris A, Reuland DS, **Nielsen ME**, Teal R, Vu M, Clemens JQ, and Tan HJ (2024). Perceived vs. actual decision-making behavior among urologists: A convergent, parallel, mixed-methods study of self-reported practice. *Urology* 183: 78-84. PMID 37996015
  14. Weiss K\*, Abimbola O, Mueller D, Basak R, Basch E, Parisse T, Hamad J, **Nielsen M**, Tan HJ, Wallen E, Bjurlin M, and Smith AB (2024). Feasibility, acceptability, and outcomes of a mobile health tool for radical cystectomy recovery. *J Urol* 211(2): 266-275. PMID: 37972245
  15. Garg T\*, Frank K, Johns AM, Rabinowitz K, Danella J, Kirchner HL, **Nielsen ME**, McMullen CK, Murphy T, and Cohen H (2024). Geriatric assessment-derived deficit accumulation and patient-reported treatment burden in older adults with bladder cancer. *J Am Geriatrics Society*, 72(2): 490-502. PMID: 37974546
  16. McKenzie CP\*, Straube LE, Webster C, **Nielsen M**, and Stuebe AM (2024). Reducing opioid prescribing after cesarean delivery by utilizing a tailored opioid prescribing algorithm: a quality improvement initiative. *Am J Perinatology*, 41 (S 01): e2934-e2940. PMID 37774746
  17. Kashkoush J, Gupta M, Meissner MA, **Nielsen ME**, Kirchner HL, and Garg T\* (2023). Performance characteristics of a rule-based electronic health record algorithm to identify patients with gross and microscopic hematuria. *Meth Infor Med.* 62(5-06): 183-192. PMID: 37666279
  18. Gallagher K\*, Bhatt N, Clement K, Zimmerman E, Khadhour S, MacLennan S, Kulkarni M, Gaba F, Anbarasan T, Asif A, Light A, Chan V, Nathan A, Cooper D, Aucott L, Marcq G, Teoh JY, Hensley P, Duncan E, Goulao B, O'Brien T, **Nielsen M**, Mariappan P, and Kasivisvanathan V (2023). Audit, feedback, and education to improve quality and outcomes in nonmuscle invasive bladder cancer treatment: Protocol for a multicenter international observational study with an embedded cluster randomized trial. *JMIR Res Protoc* 12:242254. PMID: 37318875
  19. Birken SA, Matulewicz R, Pathak R, Wagi CR, Peluso AG, Bundy R, Witek L, Krol B, Parchman ML, **Nielsen ME**, and Dharod A (2023). Toward the de-implementation of computed tomography urogram for patients with low- to intermediate-risk microscopic hematuria: A mixed-method study of factors influencing continued use. *Urology Practice* 10(5): 511-519. PMID: 37318875

20. Entzel P\*, **Nielsen M**, Weiss S, Park Y, Lu R, Baskin-Miller J, Hutchinson B, Obioma P, An X, and Balfanz G (2023). How do I reduce variation in red blood cell transfusion practices in a large integrated health care system? *Transfusion* 63(6): 1113-1121. PMID: 37190781
21. Chadwick SJ\*, Dave O, Frisbie J, Scales CD, **Nielsen ME**, and Friedlander DF (2023). Incidence and cost of potentially avoidable emergency department visits for renal colic. *Am J Managed Care* 29(11): e322-e329. PMID: 37948652
22. Tan HJ\*, Chung AE, Gotz D, Deal AM, Heiling HM, Teal R, Vu M, Meeks WD, Fang R, Bennett AV, **Nielsen ME**, and Basch EM. (2023) Electronic health record use and perceptions among urologic surgeons. *Applied Clinical Informatics*. 14: 279-289. PMID: 37044288
23. Song L, Keyserling T, Chen R, Ma C, Xu S, Shieh K, Fuller G, **Nielsen ME**, Northouse L, Tan X, and Rini C (2023). Role, race, and place: Prostate cancer disparities in patients' and partners' health outcomes and psychosocial factors. *Cancer Medicine* 12(8): 9857-9867. PMID: 36748581
24. Khadouri S\*, Gallagher KM, MacKenzie KR, Shah TT, Gao C, Moore S, Zimmerman EF, Edison E, Jefferies M, Nambiar A, Anbarsan T, Mannas MP, Lee T, Marra G, Gomez Rivas J, Marcq G, Assmus MA, Ucar T, Claps F, Boltri M, La Montagna G, Burnhope T, Nkwam N, Austin T, Boxall NE, Downey AP, Sukhu TA\*, Anton-Juanilla M, Rai S, Chin YF, Moore M, Drake T, Green JSA, Goulao B, MacLennan G, **Nielsen M**, McGrath JS, Kasivisvanathan V; IDENTIFY Study group (2022). Developing a diagnostic multivariable prediction model for urinary tract cancer in patients referred with haematuria: Results from the IDENTIFY Collaborative Study. *Eur Urol Focus*, S2405-4569(22)00129-8. PMID 35760722
25. Hwang S\*, Birken SA, **Nielsen ME**, Elston-Lafata J, Wheeler SB, and Spees LP (2022). Understanding the multilevel determinants of clinicians' imaging decision-making: Setting the stage for de-implementation of low-value imaging. *BMC Health Services Research*. 22(1): 1232. PMID 36199082 PMCID PMC9535949
26. Jung A\*, Crandell J, **Nielsen M**, Smith S, Bryant A, and Mayer D (2022). Relationships among uncertainty, post-traumatic stress disorder symptoms, and quality of life in non-muscle invasive bladder cancer survivors. *Supportive Care in Cancer*, 30(7): 6175-6185. PMID: 35437672
27. Oseni T, Bridget K, Pei K, **Nielsen M**, Erdahl L, Pitt SC, Diego E, Mouawad N, and Stein S (2022). Diversity efforts in surgery: Are we there yet? *Am J Surgery*, 224(1 Pt B): 259-263 PMID 35131086
28. Song L, **Nielsen ME**, Chen RC, Rini C, Keyserling TC, Idiagbonya E, Fuller GP, Northouse L, Palmer MH & Tan XM. (2022). Testing the Efficacy of a Couple-Focused,

- Tailored eHealth Intervention for Symptom Self-Management Among Men with Prostate Cancer and Their Partners: The Study Protocol. *Trials*. 23(1):12. PMID 34983621
29. Rose TL, Harrison M, Deal AM, Ramalingam S, Whang YE, Brower B, Dunn MW, Osterman CK, Heiling HM, Bjurlin MA, Smith AB, **Nielsen ME**, Tan HJ, Wallen EM, Woods ME, George D, Zhang T, Drier A, Kim WY, and Milowsky MI (2021). Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy in patients with muscle-invasive bladder cancer. *J Clin Oncol* 39(28): 3140-3148. PMID: 34428076
  30. Garg T\*, Johns A, Young AJ, **Nielsen ME**, Tan HJ, McMullen CK, Cohen H, Johns AM, Kirchner HL, Cohen H, and Murphy T (2021). Geriatric conditions and treatment burden following diagnosis of non-muscle-invasive bladder cancer in older adults: A population-based analysis. *J Geri Oncology*, 12(7): 1022-1030. PMID 33972184
  31. Khadouri S\*, Gallagher KM, MacKenzie KR, Shah TT, Gao C, Moore S, Zimmerman EF, Edison E, Jefferies M, Nambiar A, Mannas MP, Lee T, Marra G, Lillaz B, Gomez Rivas J, Olivier J, Assmus MA, Ucar T, Claps F, Boltri M, Burnhope T, Nkwam N, Tanasescu G, Boxall NE, Downey AP, Lal AA, Anton-Juanilla M, Clarke H, Hw Lau D, Gillams K, Crockett M, **Nielsen M**, Takwongi Y, Chuchu N, O'Rourke J, MacLennan G, McGrath JS, Kasivisvanathan V; IDENTIFY Study group (2021). The IDENTIFY Study: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer—a multicentre observational study. *BJU Int* 128(4): 440-450. PMID: 33991045
  32. Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, Zhou M, **Nielsen M**, Smith AB, Woods M, Hayward MC, Salazar AH, Milowsky MI, Wobker SE, McGinty K, Millburn MV, Eisner JR and Kim WY (2021). Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial carcinoma: A real world experience. *Br J Cancer*, 125(9): 1251-1260. PMID: 34294892
  33. Noone AM, Lam CJK, Smith AB, **Nielsen ME**, Boyd E, Mariotto AB, and Banerjee M (2021). Machine learning methods to identify missing cases of bladder cancer in population-based registries. *JCO Clinical Informatics* 5:641-653 PMID: 34097440
  34. Damrauer JS, Roell K, Smith MA, Sun X, Kirk EL, Hoadley KA, Benefield HC, Iyer G, Solit DB, Milowsky MI, Kim WY, **Nielsen ME**, Wobker SE, Dalbagni G, Al-Ahmadie HA, Olshan A, Bochner BH, Furberg H, Troester MA, and Pietzak EJ (2021). Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer. *Clin Cancer Res* 27(16): 4599-4609. PMID: 34117034
  35. Tan HJ\*, Zhou X, Spratte BN, McMahan S, **Nielsen ME**, Lund J, Sox-Harris AH, Smith AB and Basch E (2021), Patient-reported vs. claims-based measures of health for modeling life expectancy in men with prostate cancer. *J Urol* 205(2): 434-440. PMID 32909877

36. Garg T\*, McMullen CK, Leo MC, O'Keefe-Rosetti M, Weinmann S, and **Nielsen ME** (2021). Predicting risk of multiple levels of recurrence and progression after initial diagnosis of non-muscle-invasive bladder cancer in a multi-site, community-based cohort. *Cancer*. 127(4): 520-7. PMID: 33146913
37. McMahon S\*, Basak R, Zhou X, Smith AB, Song L, Pruthi RS, Wallen EM, **Nielsen ME**, and Tan HJ (2021). Patient-reported health status, comorbidity burden, and prostate cancer treatment. *Urology* 149: 103-109. PMID: 33352164 PMCID: PMC7940590
38. Jung A\*, Crandell J, **Nielsen ME**, Smith SK and Mayer DK (2021). Post-traumatic stress disorder symptoms in non-muscle-invasive bladder cancer survivors: A population-based study. *Urol Oncol*. 39(4): 237.e7-237.e14. PMID: 33308978
39. Gessner KH\*, Jung J, Cook HE, Graves JL, McNaull P, Chidgey B\*, Mann J, Woody N, Deal AM, Coward RM, Figler B, Borawski K, Bjurlin MA, Raynor M, Tan HJ\*, Viprakasit D, Wallen E, **Nielsen ME**, and Smith AB (2021). Implementation of post-operative standard opioid prescribing schedules reduces opioid prescriptions without change in patient-reported outcomes. *Urology*, 148: 126-33. PMID: 33217455
40. Wallis CJD\*, Sayyid R, Manyevitch R, Perlis N, Lokeshwar VB, Fleshner NE, Terris MK, **Nielsen ME**, and Klaassen Z (2021). Diagnostic utility of axial imaging in the evaluation of hematuria: A systematic review and critical appraisal of the literature. *Can Urol Assoc J*, 15(2): 48-55. PMID: 32745004
41. Osterman CK, Deal AM, McCloskey H, Nyrop KA, Bjurlin MA, Tan HJ, **Nielsen ME**, Milowsky MI, Muss HB, and Smith AB (2021). Impairment and longitudinal recovery of older adults treated with radical cystectomy for muscle-invasive bladder cancer. *J Urol*, 205(1): 94-99. PMID: 32716672
42. Song L, Guo PR, Tan XM, Chen R, **Nielsen ME**, Birken S, Koontz B, Northouse L, and Mayer DK (2021). Enhancing survivorship care planning for patients with localized prostate cancer using a couple-focused, web-based mHealth program: The results of a pilot feasibility study. *J Cancer Survivorship*. 15(1): 99-108. PMID 32681304.
43. Mohan C\*, Bjurlin MA, Rotter J, Tan HJ, **Nielsen ME**, Basch E, Samuel C, Kent E, and Smith AB (2020). The association between patient experience and healthcare outcomes using SEER-CAHPS patient experience and outcomes among cancer survivors. *J Geri Oncol*. S1879-4068(20)30498-7. PMID: 33277226
44. Ehlers M\*, Gore JL, Bjurlin M, Tan HJ, Narang G, **Nielsen ME**, Zhu A, Deal A, and Smith AB (2020). A national cross-sectional survey of financial toxicity among bladder cancer patients. *Urol Oncol* 39(1):76.e1-76.e7 PMID: 33268274
45. Eulitt P, Altun E, Sheikh A, Wong T, Woods M, Rose TL, Wallen E, Pruthi R, Smith A, **Nielsen ME**, Whang Y, Kim W, Godley P, Basch E, David G, Ramirez J, Deal A, Rathmell

- WK, Chen R, Bjurlin M, Lin W, Lee J, and Milowsky M (2020). Pilot study of 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-magnetic resonance imaging (MRI) for staging of muscle-invasive bladder cancer. *Clin Genitourinary Cancer*. 18(5): 378-386.e1. PMID: 32147364
46. Garg T\*, Young AJ, O’Keefe-Rosetti M, McMullen CK, **Nielsen ME**, Murphy TE, and Kirchner HL (2020). Association between metabolic syndrome and recurrence in older adults treated for non-muscle-invasive bladder cancer. *Urol Oncol*, S1078-1439(20)30150-2. PMID: 32409197.
47. Jung A\*, **Nielsen ME**, Crandell JL, Palmer MH, Smith SK, Bryant AL, and Mayer DK (2020). Health-related quality of life among non-muscle-invasive bladder cancer survivors: A population-based study. *BJU International*. 125(1): 38-48. PMID: 31381249
48. Leo M, McMullen CK, Weinmann S, O’Keefe-Rosetti M, Garg T, and **Nielsen ME** (2020). External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system. *Urol Oncol*, 38(2): 39 e21-39.e27 PMID: 31711836
49. Smith AB, Samuel C, Zhu A, Deal A, Jonsson M, Mueller D, Mahbooba Z, Bennett A, Chung A, **Nielsen ME**, Pruthi R, Tan R, Wallen E, Wang A, Reeve B, and Chen R (2020). Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. *Urol Oncol* 39(1): 77.e1-77.e8. PMID: 32819814
50. Lam CJK, Warren JL, **Nielsen ME**, Smith A, Boyd E, Barrett MJ and Mariotto AB (2020). Using the SEER-Medicare data to assess incident chronic myeloid leukemia and bladder cancer cases missed by cancer registries. *J Natl Cancer Inst Monogr* (55):31-38 PMID: 32412074
51. Garren B\*, Woody N, Sutherland RW, McNaul P, **Nielsen M**, Lawrence M, Bukowski T, McCall C, Chidgey B, Ricketts K and Ross SS (2019). Opioid prescribing patterns, storage, handling and disposal in post-operative pediatric urology patients. *J Pediatr Urol*. 15(3): 260.e1-260.e7 PMID 31010641
52. Georgieva MV\*, Wheeler SB, Erim D, Smith-Bindman R, Loo R, Ng C, Garg T, Raynor M, and **Nielsen ME** (2019). Comparison of the harms, advantages, and costs associated with alternative guidelines for the evaluation of hematuria. *JAMA Intern Med*. 179(10): 1352-1362. PMID: 31355874. PMCID: PMC6664383
53. Smith AB, Mueller D, Garren B, Tan HJ, Wallen E, Woods M, Pruthi R, and **Nielsen M** (2019). Using qualitative research to reduce readmissions and optimize perioperative cystectomy care. *Cancer* 125(20): 3545-3553. PMID: 31299091

54. McMullen CK, O’Keefe-Rosetti M, Weinmann S, Leo ML, and **Nielsen ME** (2019). Clinical use cases for a superficial bladder cancer risk assessment tool. *Permanente Journal*. 23:18-276. PMID: 31496500 PMCID: PMC6730961
55. Garry EM\*, Buse JB, Gokhale M, Lund JL, **Nielsen ME**, Pate V, and Sturmer T (2019) Study design choices for evaluating comparative safety of diabetic medications: An evaluation of pioglitazone and bladder cancer risk among older US adults with type-2 diabetes. *Diabetes, Obesity and Metabolism*. 21(9): 2096-2106. PMID: 31087620
56. Check DK\*, Aaronson DS, **Nielsen ME**, Lee VS, Roh JM, Kushi LH, Tang L, and Kwan ML (2019). Perioperative intravesical chemotherapy for patients with non-muscle invasive bladder cancer: Understanding the extent and sources of variation in guideline-recommended use. *Urology*. 124: 107-112. PMID: 30359712
57. Pawloski PA, Brooks GA, **Nielsen ME** and Olson-Bullis B (2019). A systematic review of clinical decision support systems for clinical oncology practice. *J Natl Compr Canc Netw*. 17(4): 331-338. PMID 30959468; PMCID: PMC6563614.
58. Rosenkrantz A, Heilbrun M, **Nielsen ME**, and Duszak R (2018). Characteristics of physicians and other providers frequently ordering intravenous pyelograms. *J Am Coll Radiol*. 16(9 Pt A): 1153-1157. PMID: 30584041
59. Khan S\*, Cai J, **Nielsen ME**, Troester MA, Mohler JL, Fontham ETH, Farnan L, Drake BF, Olshan AF, and Bensen JT (2018). The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. *Cancer Causes Control*. 29(11): 1143-50. PMID: 3026717
60. Garg T\*, Young AJ, O’Keefe-Rosetti M, McMullen CK, **Nielsen ME**, Kirchner HL, and Murphy TE (2018). Association of treatment for superficial bladder cancer with ten year mortality in older adults with multiple chronic conditions. *Cancer* 124(23):4477-4485. PMID: 30289971.
61. Heijnsdijk EAM\*, Nieboer D, Garg T, Lansdorp-Vogelaar I, de Koning HJ, and **Nielsen ME** (2018). Cost-effectiveness of surveillance schedules in adults with non-muscle invasive bladder cancer. *BJU International*. 123(2):307-12 PMID: 30066439
62. McMullen CK, **Nielsen ME**, Firemark A, Price P, Nakatani D, Tuthill J, McMyn R, Odisho A, Myers, MO, Shibata D, and Gilbert SD (2018). Designing for impact: identifying stakeholder-driven interventions in support of recovery after major cancer surgery. *Supportive Care in Cancer*. 26(12): 4067-4076. PMID: 29876832.
63. Smith AB, Meyer AM, Meng K, **Nielsen ME**, Pruthi RS, Wallen EM, Woods ME, and Tan HJ (2018). The relationship of travel distance with cystectomy access and outcomes. *Urol Oncol*. 36(6): 308.e1-308.e9. PMID: 29566978

64. Jung A\*, **Nielsen ME**, Crandell JL, Palmer MH, Bryant AL, Smith S, and Mayer DK (2018). Quality of life in non-muscle-invasive bladder cancer survivors: A systematic review. *Cancer Nursing*. 42(3): E21-E33. PMID: 29863576
65. Song L, Dunlap K, Mayer D, Tan X, Chen R, **Nielsen M**, Asafu-Adjei J, Koontz B, Birken S and Northouse L (2018). Enhancing survivorship care planning for patients with localized prostate cancer using a couple-focused web-based tailored symptom self-management program. *JMIR Research Protocols*. 7(2): e51 PMID: 29483070
66. Bandari J\*, **Nielsen ME**, Jacobs BL and Smith KJ (2018). Cost-effectiveness of single versus confirmatory urinalysis in the evaluation of asymptomatic microhematuria. *Urology Practice*. 5(6): 427-432. <https://doi.org/10.1016/j.urpr.2017.12.001>
67. Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS; Flexible Blue Light Study Group Collaborators, Bazargani S, Cookson M, Cross B, Lallas CD, Djaladat H, Gomella L, Johnson M, McKiernan J, Mann M, Merrill M, **Nielsen M**, Pierorazio P, Pruthi R, Sankin A, Schuckman A, Shabsigh A, Shah JB, Smith A, Stratton K, Taylor J, Weight C, and Wenske S (2017). Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate (HAL) in the surveillance of bladder cancer: A Phase III, comparative, multi-center study. *J Urol* 199(5): 1158-1165 PMID: 29203268
68. Casilla-Lennon M, Choi SK, Deal AM, Bensen JT, Narang G, Filippou P, McCormick B, Pruthi R, Wallen EM, Tan HJ, Woods M, **Nielsen M** and Smith AB (2017). Financial toxicity in bladder cancer patients—reasons for delay in care and effect on quality of life. *J Urol*. 199(5): 166-1173. PMID: 29155338
69. Broughman J, Basak RS, **Nielsen ME**, Reeve B, Usinger DS, Spearman K, Godley PA and Chen RC (2017). Prostate cancer patient characteristics associated with a strong preference to preserve sexual function and receipt of active surveillance. *J Nat Cancer Inst*. 110(4): 420-425. PMID: 29045679
70. Smith AB, Jaeger B, Pinheiro LC, Edwards LJ, Tan HJ, **Nielsen ME** and Reeve BB (2017). The impact of bladder cancer on health-related quality of life. *BJU Int*. 121(4): 549-557. PMID 28990272
71. Langston JP\*, Orcutt V, Smith AB, Schultz H, Hornberger B, Deal AM, Doran T, McKibben M, Kirby EW, **Nielsen ME**, Gonzalez C and Pruthi RS (2017). Advanced practice providers in U.S. urology: A national survey of demographics and clinical roles. *Urology Practice*. 4(5): 418-24. <http://dx.doi.org/10.1016/j.urpr.2016.09.012>
72. Garg T\*, Young AJ, Kost KA, Danella JF, Larson S, **Nielsen ME** and Kirchner HL (2018). Burden of multiple chronic conditions among urologic cancer patients. *J Urol*. 199(2): 543-550 PMID 28789948

73. Pham MN, Deal AM, Ferguson JE, Wang Y, Smith AB, **Nielsen ME**, Pruthi RS and Woods ME (2017). Contemporary survival trends in penile cancer: Results from the National Cancer Database. *Urol Oncol* 35(12):674.e1-674.e9 PMID: 28882672
74. Kardos J, Wobker SE, Woods M, **Nielsen ME**, Smith AB, Wallen EM, Pruthi RS, Hayward M, Grilley-Olson J, Patel N, Weck K, Black P, Parker J, Milowsky MI, Hayes DN, and Kim WY (2017). Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer including a hypermutable phenotype. *JCO Precision Oncology*, 1: 1-12. <http://ascopubs.org/doi/figure/10.1200/PO.17.00027>
75. Smith AB, Crowell K, Woods ME, Wallen EM, Pruthi RS, **Nielsen ME**, and Lee CT (2017). Functional outcomes following radical cystectomy in women with bladder cancer: A systematic review. *Eur Urol Focus*. 3(1): 136-43. PMID: 28720359
76. Langston JP\*, Duszak R, Orcutt VL, Schultz HM, Hornberger B, Jenkins LC, Hemingway J, Hughes DR, Pruthi RS and **Nielsen ME** (2017). The expanding role of advanced practice providers in urologic procedural care. *Urology* 106: 70-75. PMID 28435035
77. Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, Broughman JR, Reeve BB, **Nielsen ME**, Usinger DS, Spearman KC, Walden S, Kaleel D, Anderson M, Sturmer T and Godley PA (2017). Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. *JAMA* 317(11):1141-1150. PMID: 28324092
78. Khan S\*, Cai J, **Nielsen ME**, Troester MA, Mohler JL, Fontham ETH, Hendrix LH, Farnan L, Olshan AO and Bensen JT (2017). The association of diabetes and obesity with prostate cancer progression: HCaP-NC. *The Prostate*. 77(8): 878-87. PMID 28261834
79. Salloum RG\*, O'Keefe-Rosetti M, Ritzwoller DP, Hornbrook M, Noua K and **Nielsen ME** (2017). Use of evidence-based prostate cancer imaging in a non-governmental integrated healthcare system. *J Oncol Practice*. 13(5): e441-e450 PMID: 28221895
80. Stitzenberg KB, Chang Y, Smith AB, Meyers MO and **Nielsen ME** (2017). Impact of location of readmission on outcomes after major cancer surgery. *Annals of Surgical Oncology*. 24(2): 319-29. PMID: 27613557
81. Khan, S\*, Cai J, **Nielsen ME**, Troester MA, Mohler JL, Fontham ET, Hendrix LH, Farnan L, Olshan AF and Bensen JT (2016). The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. *Cancer Causes and Control* 27(12): 1475-85. PMID: 27830399
82. Rose TL\*, Deal AM, Ladoire S, Crehange G, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Lontos M, Yu EY, Pal SK, Chen RC, Wang A, **Nielsen ME**, Smith AB and Milowsky MI (2016). Patterns of bladder

- preservation therapy utilization for muscle-invasive bladder cancer. *Bladder Cancer* 2(4): 405-413 PMID: 28035321 PMCID: PMC5181658
83. Mak KS, Cheng JS, Smith AB, Chen RC, **Nielsen ME**, Milowsky MI, Feldman AS, Matthews JE, Lee R, Niemierko A, Zietman AL, Shipley WU, Clayman RH, Eidelman A, Drumm M and Efstathiou JA (2016). Quality of life in long-term survivors of muscle-invasive bladder cancer. *Int J Rad Oncol.* 96(5): 1028-36. PMID: 27727064
  84. McKibben MJ\*, Kirby EW, Langston J, Raynor MC, **Nielsen ME**, Smith AB, Wallen EM, Woods ME, and Pruthi RS (2016). Projecting the urology workforce over the next 20 years. *Urology.* 98: 21-26. PMID: 27491965
  85. Johnson DC\*, Mueller DE, Deal AM, Smith AB, Woods ME, Wallen EM, Pruthi RS and **Nielsen ME** (2016). Integrating patient preferences into treatment decisions for men with prostate cancer at the point of care. *J Urol.* 196(6): 1640-44. PMID: 27346032
  86. Rose TL\*, Deal AM, Krishnan B, **Nielsen ME**, Smith AB, Kim WY, and Milowsky MI (2016). Racial disparities in survival in metastatic renal cell carcinoma in the targeted therapy era. *Cancer* 122(19): 2988-95. PMID: 27341404
  87. Rose TL\*, Deal AM, **Nielsen ME**, Smith AB and Milowsky MI (2016). Sex disparities in chemotherapy use and survival in patients with advanced bladder cancer. *Cancer.* 122(13): 2012-20. PMID: 27224661
  88. Ellis SD\*, Chen RC, Dusetzina SB, Wheeler SB, Jackson GL, **Nielsen ME**, Carpenter WR, and Weinberger M (2016). Are small reimbursement changes enough to change cancer care? Reimbursement variation in prostate cancer treatment. *J Oncology Practice* 12(4): e423-36. PMID: 26957641
  89. Pruthi NS, Deal A, Langston J, Kirby EW, McKibben MJ, Gonzalez C, McKenna P, **Nielsen ME**, Raynor MC, Smith AB, Wallen EM, Woods ME and Pruthi RS (2016). Factors related to job satisfaction in urology. *Urology Practice* 3(3): 169-174.
  90. Ording AG\*, **Nielsen ME**, Smith AB, Horvath-Puho E and Sorensen HT (2016). Venous thromboembolism and effect of comorbidity in bladder cancer: A Danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011. *Urol Oncol.* 34(7): 292.e1-8. PMID: 26971189
  91. Brooks SA\*, Khandani AH, Wallen EM, Woods ME, Sills T, Lee Y, Lin W, Arreola A, Kim WY, Milowsky MI, Smith AB, **Nielsen ME**, Fielding JR, Parker JS, Lalush DS and Rathmell WK (2016). Alternate metabolic programs define regional variation of relevant biological features in renal cell carcinoma progression. *Clin Cancer Res.* 22(12): 2950-9. PMID: 26787754

92. Song L\*, Toles MP, Bai J, **Nielsen ME**, Bailey DE, Sleath B and Mark B (2015). Patient participation in communication about treatment decision-making for localized prostate cancer during consultation visits. *Health*. 7, 1419-1429.  
<http://dx.doi.org/10.4236/health.2015.711156>
93. Janda G, Deal A, Yang H, **Nielsen M**, Smith A, Pruthi RS, Wallen E, Woods M and Raynor M (2015). Single institution experience with robotic partial nephrectomy for renal masses greater than 4cm. *J Endourol* 30(4): 384-9. PMID 26597172
94. Butler A\*, Olshan A, Kshirsagar A, Edwards J, **Nielsen ME**, Wheeler S and Brookhart MA (2015). Trends in anemia management in hemodialysis patients with cancer. *Am J Nephrology* 42(3): 206-15. PMID 26439712
95. Spencer ES, Deal AM, Pruthi NR, Gonzalez C, Kirby EW, Langston J, McKenna P, McKibben MJ, **Nielsen ME**, Raynor MC, Wallen EM, Woods ME, Pruthi RS and Smith AB (2015). Gender differences in compensation, job satisfaction, and other practice patterns in urology. *J Urol*. 195(2): 450-5. PMID: 26384452
96. Ellis SD\*, **Nielsen ME**, Carpenter WR, Jackson GL, Wheeler SB, Liu H and Weinberger M (2015). Gonadotropin-releasing hormone agonist overuse: Urologists' response to reimbursement and characteristics associated with persistent overuse. *Prostate Cancer Prostatic Diseases* 18(2): 173-81. PMID: 25849354
97. Rose TL\*, Deal AM, Basch E, Godley P, Rathmell WK, Kim WY, Whang Y, Dunn M, Wang A, **Nielsen ME**, Pruthi R, Wallen E, Woods M, Smith A and Milowsky MI (2015). Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. *Urol Oncol* 33(9):386.e1-6. PMID: 26122712
98. Song L\*, Rini C, Deal AM, **Nielsen ME**, Kineer P, Teal R, Johnson DC, Dunn MW, Mark B, and Palmer M (2015). Improving couples' quality of life through a web-based, couple-oriented prostate cancer education intervention. *Oncology Nursing Forum*. 42(2): 183-92. PMID: 25806885
99. Morris BB\*, Farnan L, Song L, Addington E, Mishel M, Mohler JL, Chen RC, **Nielsen ME** and Bensen JT (2015). Treatment decisional regret among men with prostate cancer: Racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC). *Cancer*. 121(12): 2029-35. PMID: 25740564
100. Lewis CL, Adams J, Tai-Seale M, Huang Q, Knowles SB, **Nielsen ME**, Pignone MP and Frosch DL (2015). A randomized controlled effectiveness trial of PSA screening decision support interventions in two primary care settings. *J Gen Intern Med*. 30(6): 810-16. PMID: 25666221

101. Butler A\*, Olshan A, Kshirsagar A, Edwards J, **Nielsen ME**, Wheeler S and Brookhart MA (2015). Cancer incidence among US Medicare end-stage renal disease patients on hemodialysis, 1996-2009. *Am J Kidney Dis.* 65(5): 763-72. PMID: 25662835
102. Stitzenberg K, Chang YK, Smith AB and **Nielsen ME** (2015). Exploring the burden of inpatient readmissions after major cancer surgery. *J Clin Oncol.* 33(5):455-64. PMID: 25547502
103. Pruthi A, **Nielsen ME**, Raynor MC, Woods ME, Wallen EM and Smith AB (2015). Readability of online patient education materials in urologic oncology: A need for simple communication. *Urology.* 85(2): 351-6. PMID: 25623686
104. Chen RC, Carpenter WR, Kim M, Hendrix LH, Agans RP, Meyer AM, Hoffmeyer A, Reeve BB, **Nielsen ME**, Usinger DS, Strigo TS, Jackman AM, Anderson M and Godley PA (2015). Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS). *J Comp Eff Res.* 4(1):3-9. PMID: 25565065
105. Johnson DC\*, Vukina J\*, Smith AB, Meyer AM, Wheeler S, Kuo TM, Tan HJ, Woods ME, Raynor MC, Wallen EM, Pruthi RS and **Nielsen ME** (2015). Preoperatively misclassified, surgically removed benign renal masses: A systematic review of surgical series and United States population-level burden estimate. *J Urol.* 193(1): 30-5. PMID: 25072182
106. Begg CB, Seshan VE, Zabor EC, Furburg H, Arora A, Shen R, Maranchie JK, **Nielsen ME**, Rathmell WK, Signoretti S, Tamboli P, Choueiri TK, Hakimi AA, and Hsieh JJ (2014). Genomic investigation of etiologic heterogeneity: Methodologic challenges. *BMC Medical Research Methodology.* 14(1):138 PMID: 25532962 PMCID: PMC4292824
107. Feng MA\*, McMillan D, Crowell K, Muss H, **Nielsen ME** and Smith AB (2015). Geriatric assessment in surgical oncology: a systematic review. *J Surg Research* 193(1): 265-72. PMID: 25091339
108. Tan HJ\*, Meyer AM, Kuo TM, Smith AB, Wheeler SB, Carpenter WR and **Nielsen ME** (2014). Provider-based research networks and the diffusion of surgical technologies among patients with early stage kidney cancer. *Cancer* 121(6): 836-43. PMID: 25410684
109. Johnson DC\*, Riggs SB, **Nielsen ME**, Matthews JE, Woods ME, Wallen EM, Pruthi RS and Smith AB (2014). Nutritional predictors for complications following radical cystectomy. *World J Urol.* 33(8): 1129-37. PMID: 25240535
110. Fifer GL, Raynor MC, Selph P, Woods ME, Wallen EM, Viprakasit DP, **Nielsen M**, Smith AM and Pruthi RS (2014). Robotic Ureteral Reconstruction Distal to the Ureteropelvic Junction: A Large Single Institution Clinical Series with Short Term Follow-Up. *J Endourology* 28(12): 1424-8. PMID: 25230048

111. Smith AB\*, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, Milowsky MI and **Nielsen ME** (2014). Muscle-invasive bladder cancer: Evaluating treatment and survival in the National Cancer Data Base. *BJU International*. 114(5): 719-26. PMID: 24325202
112. McMillan D\*, Viera AJ, Matthews J, Raynor MC, Woods ME, Pruthi RS, Wallen EM, **Nielsen ME** and Smith AB (2014). Resident involvement and experience as predictive factors for perioperative outcomes following robotic prostatectomy. *World J of Urol*. 33(6): 793-9. PMID: 24985554
113. Smith AB\*, Horvath-Puho E, **Nielsen ME**, Lash TL, Baron JA and Sorensen HT (2014). Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma, *Urol Oncol* 32(4):466-72. PMID: 24767684
114. Selph JP, Whited WM, Smith AB, Matthews J, Pruthi RS, Wallen EM, **Nielsen ME** and Woods ME (2014). Metabolic syndrome as a predictor for postoperative complications following urologic surgery. *Urology* 83(5):1051-9. PMID: 24656508
115. Brooks SA\*, Brannon AR, Parker JS, Fisher JC, Sen O, **Nielsen ME** and Rathmell WK (2014). ClearCode34: a prognostic risk predictor for clear cell renal cell carcinoma. *Eur Urol*. 66(1): 77-84. PMID: 24613583
116. Song L\*, Ji Y, Knafl G and **Nielsen ME** (2014). Quality of life and health status among prostate cancer survivors and non-cancer population controls. *Urology* 83(3): 658-63. PMID: 24581528
117. Chen RC, Hendrix LH, Carpenter WR, Bainbridge J, Wang ZA, **Nielsen ME** and Godley PA (2014). Receipt of guideline-concordant treatment in elderly prostate cancer patients. *Int J Radiat Oncol Biol Phys* 88(2): 332-8. PMID: 24411605
118. Smith AB\*, Yu H, Deal AM, Muss HB, Matthews J and **Nielsen ME** (2014). Sarcopenia as a predictor for complications and survival following radical cystectomy. *J Urol* 191(6):1714-20. PMID: 24423437
119. Johnson DC\*, **Nielsen ME**, Matthews J, Woods ME, Wallen EM, Pruthi RS, Milowsky MI and Smith AB (2014). Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. *BJU International*. 114(2): 221-8. PMID: 24274722
120. **Nielsen ME**, Mallin K, Weaver MA, Palis B, Stewart A, Winchester DP and Milowsky MI (2013). The association of hospital volume with conditional 90-day mortality after cystectomy: An analysis of the National Cancer Database. *BJU International*. 114(1): 46-55. PMID: 24219110 PMCID: PMC4019706
121. **Nielsen ME**, Smith AB, Meyer AM, Kuo TM, Tyree S, Kim WY, Milowsky MI, Pruthi RS and Millikan R (2014). Trends in stage-specific incidence rates for urothelial carcinoma of

- the bladder in the United States: 1988-2006. *Cancer* 120(1): 86-95. PMID: 24122346  
PMCID: PMC3964001
122. Langston JP\*, Kirby EW\*, **Nielsen ME**, Smith AB, Woods ME, Wallen EM and Pruthi RS (2014). Economic impact of career choices in urology. *J Urol.* 191(3):755-60. PMID: 24096119
  123. Howard K, Brenner A, Lewis C, Sheridan S, Crutchfield T, Hawley S, **Nielsen ME** and Pignone MP (2013). A comparison of US and Australian men's values and preferences for PSA screening. *BMC Health Services Research* 13(1): 388. PMID: 24093428 PMCID: PMC3852221
  124. Olshan AO, Kuo TM, Meyer AM, **Nielsen ME**, Purdue MP and Rathmell WK (2013). Racial difference in histologic subtype of renal cell carcinoma. *Cancer Medicine* 2(5):744-9. PMID: 24403240 PMCID: PMC3892806
  125. Trantham LC\*, **Nielsen ME**, Mobley LR, Wheeler SB, Carpenter WR and Biddle AK (2013). Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy. *Cancer* 119(19): 3523-30. PMID: 23893821 PMCID: PMC3788002
  126. Smith AB\*, Woods ME, Raynor MC, **Nielsen ME**, Wallen EM and Pruthi RS (2013). Prevention and management of complications following robot-assisted radical cystectomy: lessons learned after >250 consecutive cases. *World J Urol* 31(3): 441-6. PMID: 23269587 PMCID: PMC3636191
  127. Zhang Y\*, Denton BT and **Nielsen ME** (2013). Comparison of surveillance strategies for low risk bladder cancer patients. *Medical Decision Making*;33(2):198-214. PMID: 23178638
  128. Smaldone MC, Simhan J, Kutikov A, Canter DJ, Starkey R, Zhu F, **Nielsen ME**, Stitzenberg KB, Greenberg RE and Uzzo RG (2013). Trends in regionalization of radical cystectomy in three large Northeastern states from 1996-2009. *Urol Oncol* 31(8): 1663-9. PMID: 22687566
  129. Mmeje CO, Nunez-Nateras R, **Nielsen ME**, Pruthi RS, Smith A, Wallen EM, Humphreys MR, Woods ME and Castle EP (2012). Oncologic outcomes for lymph-node positive urothelial carcinoma patients treated with robot-assisted radical cystectomy with mean follow-up of 3.5 years. *Urol Oncol* 31(8): 1621-7 PMID: 22534088
  130. Raynor MC, Lavien G, **Nielsen M**, Wallen EM and Pruthi RS (2013). Elimination of preoperative mechanical bowel preparation in patients undergoing cystectomy and urinary diversion. *Urol Oncol* 31(1): 32-5. PMID: 21719323
  131. Song L\*, Chen RC, Bensen JT, Knafel GJ, **Nielsen ME**, Farnan L, Wallen EM, Mishel M, Pruthi RS, Mohler JL and Godley PA (2012). Who makes the decision regarding treatment

- for clinically localized prostate cancer, patient or physician? Results from a population-based study. *Cancer*, 119(2): 421-8 PMID: 22786794
132. Yang Y, Li T and **Nielsen ME** (2012). Aging and cancer mortality: Dynamics of change and sex differences. *Exp Gerontol*. 47(9): 695-705. PMID: 22750030 PMCID: PMC3418386
  133. **Nielsen ME**, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N and Lotan Y (2012). Reported use of intravesical therapy for non-muscle-invasive bladder cancer: results from the BCAN survey. *BJU International*. 110(7): 967-72. PMID: 22487336
  134. Ferguson JE\*, Goyal R, Raynor M, **Nielsen ME**, Pruthi RS, Brown P and Wallen E (2012). Cost analysis of robot-assisted laparoscopic versus hand-assisted laparoscopic partial nephrectomy. *J Endourol* 26(8):1030-7. PMID: 22384936
  135. Smith AB\*, Raynor M, Amling CL, Busby JE, Castle E, Davis R, **Nielsen M**, Thomas R, Wallen EM, Woods M and Pruthi RS (2012). Multi-institutional analysis of robotic radical cystectomy for bladder cancer: Perioperative outcomes and complications in 227 patients. *J Laparoendosc Adv Surg Tech A* 22(1): 17-21. PMID: 22142028
  136. Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, **Nielsen ME** and Rathmell WK (2012). Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. *Eur Urol* 61(2):258-68. PMID: 22030119 PMCID: PMC3244546
  137. Stitzenberg KB, Wong YN, **Nielsen ME**, Eggleston BL, and Uzzo RG (2012). Trends in radical prostatectomy: Centralization, robotics and access to urologic cancer care. *Cancer* 118(1): 54-62. PMID: 21717436 PMCID: PMC3184375
  138. Pruthi RS, Belsante J, Kurpad R, **Nielsen ME** and Wallen EM (2011). Robotic cystectomy and the internet: Separating fact from fiction. *Urol Oncol* 29(4): 393-7. PMID: 19576801
  139. Kurpad R\*, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, Smith L, Pettiford A, Schultz H, **Nielsen M**, Wallen EM and Pruthi RS (2011). A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions? *Urol Oncol* 29(4): 378-82. PMID: 19576797
  140. Coward RM\*, Smith A, Raynor M, **Nielsen M**, Wallen EM and Pruthi RS (2011). Feasibility and outcomes of robotic-assisted laparoscopic radical cystectomy for bladder cancer in older patients. *Urology* 77(5): 1111-14. PMID: 21333341
  141. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, **Nielsen ME**, Gonzalgo ML, Sidransky D, Schoenberg MP and Netto GJ (2010). Expression status and prognostic significance of mTOR pathway members in urothelial carcinoma of urinary bladder following cystectomy. *Cancer* 116(23): 5517-26. PMID: 20939013 PMCID: PMC3568488

142. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, **Nielsen ME**, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ghaneson S, Bhanot G, Rathmell WK (2010). Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. *Genes Cancer* 1(2): 152-63. PMID: 20871783. PMCID: PMC2943630
143. Pruthi RS, **Nielsen M**, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A and Kim W (2010). A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. *BJU Int* 106(3): 349-56. PMID: 20089114
144. Smith A\*, Kurpad R, Lal A, **Nielsen M**, Wallen E and Pruthi RS (2010). Cost analysis of robotic versus open radical cystectomy for bladder cancer. *J Urol* 183(2): 505-9. PMID: 20006882
145. Pruthi RS, **Nielsen M**, Smith A, Nix J, Kurpad R, Schultz H and Wallen E (2010). Fast track program in patients undergoing radical cystectomy: results in 362 consecutive cases. *J Amer Coll Surg* 210(1): 93-9. PMID: 20123338
146. Pruthi RS, Nix J, McRackan D, Hickerson A, **Nielsen ME**, Raynor M and Wallen EM (2010). Robotic-assisted laparoscopic intracorporeal urinary diversion. *Eur Urol* 57(6): 1013-21. PMID: 20079567
147. Pruthi RS, **Nielsen ME**, Nix J, Smith A, Schultz H and Wallen EM (2010). Robotic radical cystectomy for bladder cancer: Surgical and pathological outcomes in 100 consecutive cases. *J Urol* 183(2): 510-4. PMID: 20006884
148. Makarov DV, Landman A, Desai R, Penson DF, **Nielsen ME**, Loeb S, Leslie DL and Gross C (2010). Regional variation in total cost per radical prostatectomy in the HCUP-NIS database. *J Urol* 183(4): 1504-9. PMID: 20172559
149. Cowey CL, Amin C, Pruthi RS, Wallen EM, **Nielsen ME**, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Kim WY, Godley P, Whang YE, Fielding J and Rathmell WK (2010). A neoadjuvant clinical trial with sorafenib for patients with stage II or greater renal cell carcinoma. *J Clin Oncol* 28(9): 1502-7. PMID: 20159822
150. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, **Nielsen ME**, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ and Lotan Y (2010). Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. *J Urol* 183(1): 68-75. PMID: 19913255
151. Nix J\*, Smith A, Kurpad R, **Nielsen ME**, Wallen EM and Pruthi RS (2009). Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: Perioperative and pathologic results. *Eur Urol* 57(2): 196-201. PMID: 19853987

152. Guzzo, TJ, Bivalacqua TJ, **Nielsen ME**, Magheli A, Schoenberg MP and Gonzalgo ML (2009). Pathologic upstaging at the time of radical cystectomy is associated with worse recurrence-free survival in patients with BCG-refractory bladder cancer. *Urology* 74(6): 1276-80. PMID: 19758684
153. Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, **Nielsen ME**, Capitanio U, Jeldres C, Rigaud J, Muller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ and Lotan Y (2009). P53 expression in patients with advanced urothelial carcinoma of the urinary bladder. *BJU Int* 105(4): 489-95. PMID: 19659466
154. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, **Nielsen ME**, Capitanio U, Jeldres C, Montorsi F, Muller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI and Cote RJ (2009). p53 predictive value for pT1-2N0 disease at radical cystectomy. *J Urol* 182(3): 907-13. PMID: 19616250
155. Shariat SF, Karakiewicz PI, Godoy G, Karam J, Ashfaq R, Fradet Y, Capitanio U, Montorsi F, Bastian PJ, **Nielsen ME**, Muller S, Rigaud J, Sagalowsky AI and Lotan Y (2009). Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multi-institutional external validation study. *Clin Cancer Res* 15(22): 7012-19. PMID: 19903782
156. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, **Nielsen ME**, Muller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI and Shariat SF (2009). Multi-institutional validation of the predictive value of KI-67 labeling index in patients treated with urinary bladder cancer. *J Natl Cancer Inst* 101(2):114-9. PMID: 19141773
157. **Nielsen ME**, Schaeffer EM, Marschke P and Walsh PC (2008). High anterior release of the levator fascia improves sexual function following open radical retropubic prostatectomy. *J Urol* 180(6): 2557-64. PMID: 18930504
158. Wu I\*, **Nielsen ME**, Han M, Partin AW and Makarov DV (2008). Does laterality of positive needle biopsy in clinical T2a prostate cancer patients affect biochemical recurrence-free survival? *Urology* 72(6): 1219-23. PMID: 18372026 PMCID: PMC2633712
159. Hernandez DJ\*, **Nielsen ME**, Han M, Trock BJ, Partin AW, Walsh PC and Epstein JI (2008). Natural history of pathologically organ-confined (pT2), Gleason Score 6 or less, prostate cancer after radical prostatectomy. *Urology* 72(1): 172-6. PMID: 18304619 PMCID: PMC2603620
160. Osunkoya AO, **Nielsen ME**, Epstein JI (2008). Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: A study of 47 cases. *Am J Surg Pathol* 32(3): 468-72. PMID: 18300802

161. **Nielsen ME**, Makarov DV, Humphreys E, Mangold L, Partin AW and Walsh PC (2008). Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using the revised ASTRO criterion—"Nadir +2". *Urology* 72(2):389-93. PMID: 18279937
162. Wagner A, Muntener M, Makarov DV, **Nielsen M**, Scorpio D and Kavoussi LR (2008): Totally laparoscopic creation of a novel stapled orthotopic neobladder in a porcine model. *J Endourol* 22(1): 151-6. PMID: 18315487
163. **Nielsen ME**, Bastian, PJ, Palapattu GS, Trock BJ, Schoenberg MP, Chan T and Rogers CG (2007). Recurrence-free survival following radical cystectomy of patients downstaged by transurethral resection. *Urology* 70(6):1091-5. PMID: 18158024
164. **Nielsen ME**, Lima G, Schaeffer EM, Porter J, Cadeddu JA, Tuerk IA, Kavoussi LR (2007): The oncological efficacy of laparoscopic RPLND in the treatment of clinical stage I nonseminomatous germ cell testis cancer. *Urology* 70(6): 1168-72. PMID: 18158040
165. Hernandez DJ\*, **Nielsen ME**, Han M and Partin AW (2007). Contemporary evaluation of the D/Amico risk classification of prostate cancer. *Urology* 70(5): 931-5. PMID: 18068450
166. Muntener M\*, Schaeffer EM, Romero FR, **Nielsen ME**, Allaf ME, Brito FA, Pavlovich CP, Kavoussi LR and Jarrett TW (2007). Incidence of local recurrence and port site metastasis after laparoscopic radical Nephroureterectomy. *Urology* 70(5): 864-8. PMID: 18068440
167. Kleeberger W, Bova GS, **Nielsen ME**, Herawi M, Chuang AY, Epstein JI and Berman DM (2007). Roles for the stem cell-associated intermediate filament Nestin in prostate cancer migration and metastasis. *Cancer Research* 67(19): 9199-206. PMID: 17909025 PMCID: PMC3072059
168. **Nielsen ME**, Shariat SF, Karakiewicz PI, Amiel GE, Rogers CG, Lotan Y, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP and Palapattu, GS (2007). Delay in radical cystectomy over three months is not associated with worse clinical outcome. *BJU Int* 100(5): 1015-20. PMID: 17784888
169. Muntener M\*, Epstein JI, Hernandez DJ, Gonzalgo ML, Humphreys EB, Mangold LA, Walsh PC, Partin AW and **Nielsen ME** (2007). Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. *EurUrol* 53(4):767-76. PMID: 18060681
170. Chuang AY, **Nielsen ME**, Hernandez DJ, Walsh PC and Epstein JI (2006). The significance of positive surgical margin in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy. *J Urol* 178(4): 1306-10. PMID: 17698141
171. Tamas EF, **Nielsen ME**, Schoenberg MP and Epstein JI (2007). Lymphoepithelioma-like carcinoma of the urinary tract: A clinicopathologic study of 30 pure and mixed cases. *Mod Pathol* 20(8): 828-34. PMID: 17541442

172. Muntener M\*, **Nielsen ME**, Romero FR, Schaeffer EM, Allaf ME, Brito FAR, Pavlovich CP, Kavoussi LR, and Jarrett TW (2007). Long-term oncological outcome after laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma *Eur Urol* 51(6): 1639-44. PMID: 17240038
173. Rubio-Viqueira B, Mezzadra H, **Nielsen ME**, Jimeno A, Iacobuzio-Donahue C, Maitra A, Hidalgo, M and Altiok S (2007). Optimizing the development of targeted agents in pancreatic cancer: Tumor fine needle aspiration biopsy as a platform for novel ex vivo drug sensitivity assays. *Molecular Cancer Therapeutics* 6(2): 515-23. PMID: 17308050
174. **Nielsen ME**, Shariat SF, Amiel GE, Rogers CG, Karakiewicz PI, Lotan Y, Bastian PJ, Vazina A, Lerner SP, Sagalowsky AI, Schoenberg MP and Palapattu, GS (2007). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. *European Urology* 51(3): 699-706. PMID: 17113703
175. Huston KK, **Nielsen ME** and Gelber AC (2006) High Pressure Surgery. *American Journal of Medicine* 119: 740-2. PMID: 16945606
176. Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, **Nielsen ME**, Maitra A and Altiok S (2006). Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. *Molecular Cancer Therapeutics* 5(7):1895-1903. PMID: 16891476
177. **Nielsen ME**, Zderic S, Freedland SJ, Jarow JP (2006). Insight into the pathogenesis of varicoceles: Relationship of varicocele with body mass index, *Urology* 68(2): 392-6. PMID: 16904459
178. **Nielsen ME**, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW, Freedland SJ (2006). Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center, *J Urol* 176(2): 515-9. PMID: 16813880
179. Freedland SJ, Grubb KA, Yiu SK, **Nielsen ME**, Mangold L, Isaacs WB, Epstein JI, and Partin AW (2005). Obesity and capsular incision at the time of open radical retropubic prostatectomy, *J Urol* 174 (5): 1798-801. PMID: 16217290
180. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, **Nielsen ME**, Mangold LA, Isaacs WB, and Partin AW (2005). Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center, *J Urol* 174(3): 919-22. PMID: 16093988
181. **Nielsen ME** and Walsh PC (2005). Systematic detection and repair of subclinical inguinal hernias at the time of radical retropubic prostatectomy, *Urology* 66(5):1034-7. PMID: 16286119

**Other Peer-Reviewed Articles:**

1. Shah YB\*, Golla V, **Nielsen ME**, and Talwar R (2025). Payment bundles for prostatectomy: A new way to improve value for prostate cancer care. *UROLOGY*, Online ahead of print. PMID 40122292
2. **Nielsen ME**, Friedlander DF, and Johnson K (2024). From error to excellence: An evolving paradigm for improving the diagnostic process. *J Urol*, 213(2): 242-5. PMID 39413227
3. Galansky L\* and **Nielsen ME** (2024). From race-based to race-conscious medicine: A call to action for re-evaluating the use of race in urologic diagnostic algorithms and clinical guidelines. *J Urol*, 212(2): 372-375 PMID 38758662.
4. Bergman J, Filippou P, Suskind AM, Johnson K, Calvert E, Fero K, Lorenz KA, Giannitrapani K, Hugar L, Koo K, Leppert J, Scales CD, Terris MK, **Nielsen ME**, and Gore JL (2024). Primary palliative care in urology: Quality Improvement Summit 2021-2022. *Urology Practice* 11(3): 529-536 PMID 384511995.
5. Olmstead T, Emmerling M, Bantumilli S, Raynor M, **Nielsen ME**, Bjurlin MA, and Rose, TL (2024). Detection of testicular metastasis from renal cell carcinoma on PSMA-PET scan. *Journal of Kidney Cancer and VHL* :11(1): 49-53 PMID 38464887.
6. Patel S\*, Hamad J, **Nielsen M**, and Johnson S (2022). Management and evaluation of bladder paraganglionomas. *Asian Journal of Urology*. 9(1): 94-96. PMID 35198402.
7. Auffenberg G\*, Averch T, Barth RJ, Borza T, Brummett C, Chidgey B, Davies B, Dupree JM, Ehdaie B, **Nielsen ME**, Pais VM, Rukstalis M, Sperandeo-Fruge M, Stulberg J, Waljee JF, and Smith AB (2020). Opioid Stewardship in Urology: Quality Improvement Summit 2018. *Urology Practice*. 7(5): 349-355. PMID: 37296566
8. Chang EH\*, Tan HJ, and **Nielsen M** (2020). Management of small renal masses in patients with chronic kidney disease: Perspectives from a nephrologist. *Urol Oncol* 38(5): 533-6. PMID: 31889616
9. **Nielsen ME**, Averch T, Fredricks N, Fung GSK, Chi T, Montie J, Moore C, Puryrsko A, Remer EM, Smith-Bindman R, Sternberg K, Venkatesh A, Wolf JS, and Ziemba J (2019). American Urological Association, American College of Emergency Physicians and American College of Radiology Quality Improvement Summit 2017: Challenges and Opportunities for Stewardship of Urological Imaging. *Urology Practice* 6(5): 300-308. PMID 37317340
10. Kwan ML, Garren B, **Nielsen ME** and Tang L (2019). Lifestyle and metabolic risk factors in the prevention and treatment of bladder cancer. *Urol Oncol*. 37(6): 380-386. PMID: 29703514

11. **Nielsen ME** and Birken SA (2018). Implementation science theories to inform efforts for de-implementation of urologic oncology care practices resulting in overuse and misuse. *Urol Oncol*. 36(5): 252-6. PMID: 29566976
12. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, **Nielsen ME** and Lotan Y (2017). Bladder Cancer. *Nature Reviews Disease Primers* 3:17022 PMID: 28406148
13. Makarov DV, Chrouser K, Gore JL, Maranchie J, **Nielsen ME**, Saigal C, Tessier C and Fagerlin A (2016). AUA White Paper on implementation of shared decision making into urological practice. *Urology Practice* 3(5): 355-363. PMID 37592546
14. Filippou P\*, Ferguson JE and **Nielsen ME** (2016). Epidemiology of prostate and testicular cancer. *Semin Intervent Radiol* 33:182-5. PMID: 27582605. PMCID: PMC5005081
15. Vanderwalde N\*, Chi MT, Hurria A, Galsky MD and **Nielsen ME** (2016). Treatment of muscle-invasive bladder cancer in the elderly: Navigating the tradeoffs of risk and benefit. *World J Urol* 34(1): 3-11. PMID: 26497825
16. Lerner SP, Dinney C, Kamat A, Bivalacaqua TJ, **Nielsen M**, O'Donnell M, Schoenberg MP and Steinberg G (2015). Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. *Bladder Cancer*, 1(1): 29-30. PMID: 26807434
17. Romano P, Aronsky A, Cheung D, Jarrett M, Kamal A, Lieberman J, Kresowik T, Kurlansky P, Masoudi F, McKenzie RS, **Nielsen M**, Sandel ME and Takeshita J (2015). PCPI Outcomes Ad Hoc Committee: A Toolkit for Outcome Measurement Development (33 typed pages). <https://www.thepcpi.org/pcpi/media/documents/oahc-toolkit.pdf>
18. Johnson DC\*, Greene P\* and **Nielsen ME** (2015). Surgical advances in bladder cancer: At what cost? *Urol Clin N Am*, 42(2): 235-52. PMID: 25882565
19. Sundi D, Svatek RS, **Nielsen ME**, Schoenberg MP and Bivalacqua TJ (2014). Extent of pelvic lymph node dissection during radical cystectomy: is bigger better? *Reviews in Urology* 16(4): 159-66. PMID: 25548542
20. **Nielsen ME**, Reeve BB, Hendrix LH, Agans RP, Hoffmeyer A, Usinger D, Strigo T, Jackman A, Godley PA and Chen RC (2014). Perceptions regarding treatment options for early prostate cancer—results from the North Carolina Prostate cancer Comparative Effectiveness and Survivorship Study (NC ProCESS). *DEcIDE for the AHRQ Effective Health Care Program*. .
21. Pruthi RS and **Nielsen ME** (2013). Age, gender and the urology work force: Evolving trends. *Urology Times*, June 10, 2013
22. Fraher E, Neuwahl S, **Nielsen ME** and Pruthi RS (2013). Recent trends in the urology workforce in the United States. *Urology* 82(5): 987-94. PMID: 24055244

23. Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Rathmell WK, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, **Nielsen ME** and Milowsky MI (2013). Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database—UNC GOLD. *Urol Oncol* 32(1):32.e1-9 PMID: 23434424
  
24. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Guzzo TJ, Inman BA, Kamat AM, Karsh L, **Nielsen ME**, Smith ND, Shariat SF, Svatek RS, Taylor JM; on Behalf of the Bladder Cancer Think Tank, and Bladder Cancer Advocacy Network (2013). Comprehensive handbook for developing a bladder cancer Cystectomy database *Urol Oncol* 31(6):812-26. PMID: 22056403
  
25. **Nielsen ME** (2012). Patterns of care in nonmuscle-invasive bladder cancer: results of the BCAN survey, *Audio-Digest Urology*, 35 (20):1-2.
  
26. Manvar AM\*, Rathmell WK, Ferguson J, Pruthi RS, **Nielsen ME**, Wallen EM, Nolan N, Raynor MC (2011). Carcinoma in a cadaveric transplant kidney. *Urology* 79(4): 758-60. PMID: 22014593
  
27. Manvar AM\*, Wallen EM, Pruthi RS, and **Nielsen ME** (2010). Prognostic value of CA125 in transitional cell carcinoma of the bladder. *Expert Rev Anticancer Ther* 10(12): 1877-81. PMID: 21110754
  
28. **Nielsen ME**, Trock BJ and Walsh PC (2010). Counseling patients on the benefits: Salvage versus adjuvant radiation. *JNCCN* 8(2): 228-37. PMID: 20141679
  
29. Smith AB, **Nielsen ME**, Wallen EM and Pruthi RS (2010). Current status of robot-assisted radical cystectomy. *Curr Opin Urol* 20(1): 60-4. PMID: 19875962
  
30. **Nielsen ME** and Partin AW (2008). Comparing apples and oranges: Differences in risk implication of standard definitions of biochemical failure following surgery or radiation therapy for clinically localized prostate cancer. *AUA News* 13(5): 2-3.
  
31. **Nielsen ME** and Partin AW (2007). The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. *Rev Urol* 9(2): 57-62. PMID: 17592538 PMCID: PMC1892622
  
32. **Nielsen ME**, Schaeffer EM, Veltri, R, Schoenberg MP and Getzenberg RH (2006) Urinary markers for bladder cancer detection: what's new? *Curr Opin Urol* 16(5):350-5. PMID: 16905981
  
33. **Nielsen ME**, Gonzalgo ML, Schoenberg MP and Getzenberg RH (2006). Towards critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. *World J Urol* 24(5): 499-508. PMID: 17102951

34. **Nielsen ME** and Getzenberg RH (2006) New directions in bladder cancer: Diagnosis and treatment. *European Pharmacotherapy 2005: Business Briefing*

#### **Invited Editorials:**

1. Carpinito GP, **Nielsen ME**, and Bjurlin MA (2025). Editorial comment, *J Urol*, Online ahead of print. PMID: 39927591
2. Smith-Bindman R, **Nielsen ME**, and Wang RC (2022) Unchanged diagnostic imaging for urinary stone disease: Where do we go from here? *JAMA Int Med*, 182(12): 1246-7. PMID: 36315160
3. **Nielsen ME**. (2020) Robot-Assisted Intracorporeal Orthotopic Bladder Substitution After Radical Cystectomy: Perioperative Morbidity and Oncological Outcomes — A Single-Institution Experience. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/outcomes-for-robot-assisted-intracorporeal-orthotopic-bladder-substitution-after-radical-cystectomy/108046/65/3/1>.
4. Stitzenberg KB, **Nielsen ME** (2019). Editorial comment, *J Urol* 203(3): 552. PMID: 31769722
5. Hacker Gessner K\*, **Nielsen ME** (2019). Editorial comment. *J Urol* 202(5): 1042-43. PMID: 31433250
6. Bjurlin MA, **Nielsen ME** (2019). Editorial comment. *J Urol* 202(2): 246. PMID: 31042132
7. Kaffenberger SD\*, Miller DC, **Nielsen ME** (2018). Simplifying treatment and reducing recurrence for patients with early-stage bladder cancer. *JAMA* 319(18): 1864-1865. PMID: 29800998
8. **Nielsen M** (2018). Real-World Impact of Minimally Invasive Versus Open Radical Cystectomy on Perioperative Outcomes and Spending. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/impact-of-minimally-invasive-vs-open-radical-cystectomy-on-perioperative-outcomes-and-spending/75809/65/3/1>.
9. Stitzenberg K, **Nielsen M** (2017). Editorial comment. *J Urol* 198(1):99. PMID: 28359023
10. **Nielsen ME** (2014). The legacy of Ernest A. Codman in the 21<sup>st</sup> Century. *J Urol* 192(3): 642-4. PMID: 24951851
11. **Nielsen ME** (2012). Editorial comment *Urology* 80(2): 381. PMID: 22857761
12. **Nielsen ME** (2012). Editorial comment *J Urol* 188(3): 753. PMID: 22819421

13. **Nielsen ME** (2012). Editorial comment. *J Urol* 187(6): 2093. PMID: 22498204
14. **Nielsen M** (2011). Editorial comment. *J Urol* 186(2): 493. PMID: 21679979
15. **Nielsen ME** (2010). Editorial comment. *J Urol* 183(3):975. PMID: 20083265
16. **Nielsen ME** (2010). Use and misuse of imaging by urologists. *J Urol* 184(1): 12-4. PMID: 20478581
17. **Nielsen ME** (2009). How bad are positive margins after radical prostatectomy—and how are they best managed? *J Urol* 182(4): 1257-8. PMID: 19683276
18. **Nielsen ME** (2008). Neoadjuvant gemcitabine and cisplatin: another step on the path towards improving the outcomes of patients with high-risk, invasive bladder cancer. *Cancer* 113(9): 2379-81. PMID: 18823035
19. Kavoussi LR, **Nielsen M**, Solomon SB (2006): Percutaneous image-guided urologic procedures. *Radiology* 239 (1):11-2. PMID: 16567479
20. Permpongkosol S, **Nielsen ME**, and Solomon S (2006). Percutaneous renal cryoablation. *Urology* 68 (1): s19-s25. PMID: 16857456
21. Kavoussi L, **Nielsen M**, and Solomon S (2005): Percutaneous, image-guided urological procedures: barbarians at the gate. *J Urol* 174(1):11. PMID: 15947567

#### **Book Chapters:**

1. Spaliviero M, Dalbagni G and **Nielsen ME** (2015). What to do when Bacillus Calmette-Guerin fails, in *Bladder Cancer: Diagnosis and Clinical Management*, Lerner SP, Sternberg C and Schoenberg MP (Eds.), Wiley-Blackwell, 27 typed pages (in press). ISBN: 978-1-118-67484-0
2. Kurpad R\*, Wallen EM and **Nielsen ME** (2013). Perioperative care—the radical cystectomy pathway, in *Robotic Surgery of the Bladder*, Pruthi RS and Castle EK, (Eds.), Springer. pp. 127-136 ISBN 978-1-4614-4906-5
3. Manvar A\*, Wallen EM, Pruthi RS and **Nielsen ME** (2013). Epidemiology of Prostate Cancer, in *Prostate Cancer: A Comprehensive Perspective*, Tewari A (Ed.), Springer. Chapter 23, 16 typed pages. ISBN 978-1-4471-2864-9
4. Ferguson J\*, **Nielsen ME**, Wallen EM and Pruthi RS (2013). Racial disparities and the global picture, in *Prostate Cancer: A Comprehensive Perspective*, Tewari A (Ed.), Springer, Chapter 24, 17 typed pages. ISBN 978-1-4471-2864-9

5. Nix J\*, **Nielsen ME**, Wallen EM and Pruthi RS (2011). Robotic anterior exenteration in females: Technique, current status and outcomes, in *Robotics in Genitourinary Surgery*, Menon M and Hemal A (Eds.), Springer, pp. 511-522. ISBN 978-1-84882-114-9
6. Schaeffer EM, **Nielsen ME**, Gonzalgo ML and Schoenberg MP (2006): Nerve-sparing radical cystoprostatectomy, in *Bladder Cancer: Diagnosis, Therapeutics and Management*, Lee CT and Wood DP (Eds.), Humana Press. pp. 169-77. ISBN 978-1-59745-417-9
7. **Nielsen ME** and Partin AW (2005): The role of complexed PSA (cPSA) in prostate cancer screening, in *Prostate Biopsy: Indications, Techniques and Complications*, Klein EA, ed. Contemporary Clinical Urology Series, Humana Press. pp. 29-41. ISBN 978-1-60327-078-6.
8. **Nielsen ME** (2005): Genitourinary trauma, in *The Brady Urology Manual*, Parsons JK and Wright EJ, eds. Taylor and Francis Books. pp. 263-272. ISBN: 1841844810
9. **Nielsen ME** and Wright EJ (2005): Neurourology, urodynamics and urogynecology, in *The Brady Urology Manual*, Parsons JK and Wright EJ, eds. Taylor and Francis Books. pp. 63-70. ISBN: 1841844810
10. Miles-Thomas JU, **Nielsen ME** and Nelson CP (2005): Pediatric genitourinary oncology, in *The Brady Urology Manual*, Parsons JK and Wright EJ, eds. Taylor and Francis Books. pp. 245-56 ISBN: 1841844810
11. **Nielsen ME** (2005): Interstitial cystitis and chronic pelvic pain, in *The Brady Urology Manual*, Parsons JK and Wright EJ, eds. Taylor and Francis Books. pp. 85-93. ISBN: 1841844810

### **Performance Measure Recommendations from The American College of Physicians Performance Measurement Committee**

*Writing Committee:* Nick Fitterman, MD (Chair); J. Thomas Cross, MD, MPH (Vice Chair); Steven M. Asch, MD, MPH; Eileen Barrett, MD, MPH; Peter Basch, MD; Robert Centor, MD; Catherine MacLean, MD, PhD; **Matthew E. Nielsen, MD, MS**; Robert Pendleton, MD; Laura A. Petersen, MD, MPH; Sameer D. Saini, MD, MS; Paul Shekelle, MD, MPH, PhD; Sandeep Vijan, MD, MS; Sarah J. Dinwiddie, RN, MSN, and Amir Qaseem, MD, PhD

1. Centers for Medicare and Medicaid Services 2019 Merit-Based Incentive Payment System: A Review of the Performance Measures on Cancer Screening, Coronary Artery Disease, Inflammatory Bowel Disease, Diabetes, HIV, Ischemic Vascular Disease, Obstructive Sleep Apnea, Osteoporosis, Pain Assessment/Management, Psoriasis, Schizophrenia, and Vaccination by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measurements/pmc-recommendations-nov18.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measurements/pmc-recommendations-nov18.pdf)

2. Care Coordination: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measures/preventive-care-care-coordination-review-2018.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measures/preventive-care-care-coordination-review-2018.pdf)
3. Hospital Acquired Infections: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measures/preventive-care-hospital-acquired-infections.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measures/preventive-care-hospital-acquired-infections.pdf)
4. Hypertension: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measures/preventive-care-hypertension-2018.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measures/preventive-care-hypertension-2018.pdf)
5. Heart Failure: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measures/preventive-care-heart-failure-2018.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measures/preventive-care-heart-failure-2018.pdf)
6. Sepsis: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measures/preventive-care-sepsis.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measures/preventive-care-sepsis.pdf)
7. Substance Use: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measures/preventive-care-substance-use-review.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measures/preventive-care-substance-use-review.pdf)
8. Venous Thromboembolism: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians  
[https://www.acponline.org/system/files/documents/clinical\\_information/performance\\_measurement/measures/preventive-care-vte-review.pdf](https://www.acponline.org/system/files/documents/clinical_information/performance_measurement/measures/preventive-care-vte-review.pdf)

*No presentations below were sponsored by outside entities*

### **Visiting Professorships**

- Hiding in Plain Sight: Prostate Cancer, Health Equity, and Diagnostic Excellence. Bristol Southmead Hospital NHS Trust, Bristol, England. December 4, 2025
- Faculty Retention: Changing the Conversation. Bristol Southmead Hospital NHS Trust, Bristol, England. December 4, 2025

- Hiding in Plain Sight: Prostate Cancer, Health Equity, and Diagnostic Excellence. Mount Sinai School of Medicine Department of Urology. New York, New York. October 22, 2025
- Hiding in Plain Sight: Prostate Cancer, Health Equity, and Diagnostic Excellence. Case / University Hospitals Department of Urology. Cleveland, Ohio. October 6, 2025
- Quality Assessment in Urology. Mayo Clinic Advances in Urology Course, San Juan, Puerto Rico. February 26, 2025
- Health Equity and Racial Disparities in Prostate Cancer. Mayo Clinic Advances in Urology Course, San Juan, Puerto Rico. February 28, 2025
- Hiding in Plain Sight: Prostate Cancer and Health Equity. The Ohio State University Department of Urology, Columbus, Ohio. September 13, 2024
- Faculty Retention: Changing the Conversation. The Ohio State University Department of Urology, Columbus, Ohio. September 14, 2024
- Hiding in Plain Sight: Prostate Cancer and Health Equity. The Brady Urological Institute of the Johns Hopkins Hospital, Baltimore, Maryland. May 31-June 1, 2023
- Hematuria as a Marker of Occult Urinary Tract Cancer: The Journey to High Value Care. Cedars-Sinai Department of Urology, Los Angeles, California (virtual due to COVID-19 pandemic). February 10, 2021
- Tradeoffs of Benefit, Harm and Cost in the Evaluation of Hematuria. New York University Department of Population Sciences, New York, New York, February 15, 2018
- Opportunities for Urologists to Lead through Stewardship. New York University Department of Urology, New York, New York, February 14, 2018
- Limiting overuse in evaluation of asymptomatic microhematuria: is there a safe way forward? (plenary) Southeastern Section of the American Urological Association Visiting Professor, Florida Urological Society Meeting, Orlando, Florida, September 3, 2017
- Stewardship of Imaging: Opportunities for Urologists to Lead. (plenary) Southeastern Section of the American Urological Association Visiting Professor, Florida Urological Society Meeting, Orlando, Florida, August 31, 2017
- Hematuria Evaluation: An Opportunity to Enhance Value? University of Michigan Department of Urology, Ann Arbor, Michigan, March 26, 2015

- Comparative Effectiveness of Surveillance Regimens for Low Risk Bladder Cancer. Dow Division of Health Services Research, University of Michigan Department of Urology, Ann Arbor, Michigan, March 25, 2015

### **Invited Oral Presentations**

#### *International*

- CT Urogram—Friend or Foe? Bristol Urological Institute 31<sup>st</sup> Annual Scientific Meeting. Bristol, England. December 5 2025
- Scanning the Horizon(s) in Non-muscle-invasive Bladder Cancer. Bristol Urological Institute 31<sup>st</sup> Annual Scientific Meeting. Bristol, England. December 5 2025
- Hematuria as a Marker of Occult Urinary Tract Cancer: The Journey to High Value Care. Forum fur medizinische Fortbildung / FomF [Forum for Medical Education]: General Internal Medicine Update. Zurich, Switzerland (hybrid), August 24, 2023
- Tradeoffs of Benefit, Harm and Cost in the Evaluation of H(a)ematuria. British Association of Urological Surgeons. Liverpool, England, June 27, 2018
- Needs and Opportunities for Population-based Outcomes Research in Superficial Bladder Cancer. Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark, May 12, 2012

#### *National*

- Hiding in Plain Sight: A Race-conscious Approach to the Early Detection of Prostate Cancer. Encoding Health Equity Summit 2025: From Evidence to Impact. Council of Medical Specialty Societies. Washington, DC. June 24, 2025
- Hiding in Plain Sight: Prostate Cancer, Health Equity, and Diagnostic Excellence. National Academy of Medicine Scholars in Diagnostic Excellence. Washington, DC. June 17, 2025
- Hiding in Plain Sight: Prostate Cancer and Health Equity. American Urological Association / American College of Radiology QI Summit on Diagnostic Excellence in Prostate Cancer, Linthicum, Maryland. October 25, 2024
- Appropriateness in Surgical Procedures. Moving from Volume to Value: A Roadmap for Health System Implementation. High Value Practice Alliance National Conference. October 6, 2022. Baltimore, Maryland
- The AUA Guidelines: An Inside Perspective. Society of Urologic Oncology Young Urologic Oncologists Webinar Series (virtual due to COVID-19 pandemic). April 12, 2022

- Moving from Volume to Value: A Roadmap for Health System Implementation. High Value Practice Alliance National Conference (virtual due to COVID-19 pandemic). October 7, 2021
- Cross-Mentorship of Faculty Mentees (workshop co-lead). Association of Women Surgeons He For She Committee Cross-Mentorship Workshop Series (virtual due to COVID-19 pandemic). August 9, 2021
- Hematuria: the Gateway to Bladder Cancer Diagnosis. Controversies Regarding Current Management of Patients with Hematuria, Anticipated Impact of New Guidelines, and the Future of Bladder Cancer Detection. Bladder Cancer Advocacy Network Think Tank (virtual due to COVID-19 pandemic). August 7, 2021
- Surgeons: Gatekeepers to the Opioid Epidemic? Washington State Urological Society (virtual due to COVID-19 pandemic). June 18, 2021
- AUA Science and Quality Council Update. Washington State Urological Society (virtual due to COVID-19 pandemic). June 19, 2021
- Hematuria as a Marker of Occult Urinary Tract Cancer: The Journey to High Value Care. High Value Practice Academic Alliance (virtual due to COVID-19 pandemic). March 17, 2021
- Surgeons: Gatekeepers to the Opioid Epidemic? American Hospital Association Opioid Stewardship Collaborative (virtual due to COVID-19). October 14, 2020
- Emerging Multicomponent Interventions to Address Surgeons' Contribution to the Opioid Epidemic. (plenary) Northeastern Section of the American Urological Association Annual Meeting, Syracuse, NY, September 20, 2019
- Specialty Registries and the Value Challenge. (plenary) Council of Medical Specialty Societies National Meeting, Chicago, IL, May 9, 2019
- Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High Value Care from the American College of Physicians. American College of Physicians 2019 National Meeting, Philadelphia, PA, April 11, 2019
- Multicomponent Interventions for Opioid Stewardship. American Urological Association QI Summit on Opioid Stewardship Panel Discussion, Linthicum, MD, December 8, 2018
- Thinking Outside the Box: Engagement with Professional Societies as a Platform for Impact. University of Michigan Dow Division of Health Services Research Symposium [TED format]. Ann Arbor, MI, September 14, 2018

- Surgeons: Gatekeepers to the Opioid Epidemic? American Urological Association Annual Meeting Invited Lecture. San Francisco, CA, May 19, 2018
- Challenges and Opportunities for Stewardship of Urological Imaging. American Urological Association Annual Meeting Plenary Address. San Francisco, CA, May 18, 2018
- Seeing With New Eyes: Deadoptation of Potentially Harmful Established Practices. Health Care Systems Research Network Annual Meeting, Panel Discussion on Deimplementation of Low-value Care. Minneapolis, MN, April 12, 2018
- The Impact of the Electronic Health Record on Physician Burnout and the Impending Public Health Crisis. (plenary) American Urological Association Advocacy Summit Plenary Address. Washington, DC, March 13, 2018
- The Need for Physician-Led Stewardship of Imaging in Urology. (plenary) American Urological Association Quality Improvement Summit. Linthicum, MD, October 21, 2017
- BCAN Think Tank 2017: All Grown Up. (plenary) Bladder Cancer Advocacy Network Think Tank Meeting Chair. Charlotte, NC, August 3, 2017
- Surgeon-Researcher Partnerships Supporting Bladder Cancer Research Across the HCSRN: Multiple Stakeholder Perspectives on the Value of Collaboration. Health Care Systems Research Network National Meeting Panel. San Diego, CA, March 22, 2017
- Limiting Overuse in Asymptomatic Microhematuria Evaluation: Is There a Safe Way Forward? (plenary) Society of Urologic Oncology Winter Meeting, San Antonio, TX, December 1, 2016
- Hematuria Evaluation: An Opportunity to Enhance the Value of Care? Geisinger Center for Health Research, Geisinger Clinic, Danville, PA, September 6, 2016
- Financial Toxicity: An Emerging Challenge for Bladder Cancer Care (plenary). Bladder Cancer Advocacy Network Think Tank. Denver, Colorado, August 12, 2016
- Hematuria Evaluation: An Opportunity to Enhance the Value of Care? Department of Urology, Washington University, St. Louis, MO, June 10, 2016
- Getting Dissemination and Implementation Research Published. Panelist, Mentored Training in Dissemination and Implementation Research in Cancer (MT-DIRC), Washington University, St. Louis, MO, June 10, 2016
- Hematuria Evaluation: An Opportunity to Enhance Value? Department of Urology, Oregon Health and Sciences University, Portland, OR, January 21, 2016

- Hematuria Evaluation: An Opportunity to Enhance Value? Center for Health Research, Kaiser Permanente Northwest, Portland, OR, January 20, 2016
- Active Surveillance for Prostate Cancer: Data and Outcomes (plenary). American Society for Men's Health Meeting, New Orleans, LA, May 18, 2015
- Rising Star Report: Optimizing Survivorship and Decision-making in Low Risk Bladder Cancer (plenary). American Urological Association National Meeting, New Orleans, LA, May 17, 2015  
[http://www.aaa2015.org/webcasts/webcast\\_play.cfm?videoID=1844&agendaID=7267](http://www.aaa2015.org/webcasts/webcast_play.cfm?videoID=1844&agendaID=7267)
- Optimizing Risk Stratification and Survivorship Care for Early Stage Bladder Cancer. Center for Health Research, Kaiser Permanente Northwest, Portland, OR, April 8, 2015
- Implementation Science: An Emerging Field (plenary), Health Services Research Symposium, University of Michigan Department of Urology, Ann Arbor, MI, September 19, 2014
- Unmet Clinical Needs in the Elderly: A Multidisciplinary Approach (Panel co-Chair), Bladder Cancer Advocacy Network Think Tank, San Diego, CA, August 8, 2014
- Adjuvant vs. Salvage Radiation After Prostatectomy. (plenary) University of South Florida 24<sup>th</sup> Annual Advances in Urology Meeting, Key West, FL, April 11, 2014
- Surveillance for Low Risk Bladder Cancer. (plenary) University of South Florida 24<sup>th</sup> Annual Advances in Urology Meeting, Key West, FL, April 11, 2014
- Active Surveillance for Prostate Cancer: Personalized Medicine—Are We There Yet? Southeastern Section of the American Urological Association 78<sup>th</sup> Annual Meeting, Hollywood, FL, March 20, 2014
- Bringing AUA Clinical Guidelines to Primary Care: Disseminating the AUA's Value Proposition. (plenary) American Urological Association Joint Advocacy Conference, Washington, DC, March 9, 2013
- Bladder Cancer—[Which] Elephant in the Room? Opportunities for Transformative Research. HMO Cancer Research Network / Kaiser Center for Health Research Seminar, Honolulu, Hawaii, February 8, 2013
- Active Surveillance for Prostate Cancer. American College of Surgeons Clinical Congress Panel Presentation, Chicago, Illinois, October 1, 2012

- Advances in the Treatment of Invasive Bladder Cancer. American College of Surgeons Clinical Congress Panel Presentation, San Francisco, California, October 26, 2011
- Bladder Cancer: Needs and Opportunities for Comparative Effectiveness Research. Center for Outcomes and Evidence Seminar, Agency for Healthcare Research and Quality, Rockville, Maryland, April 28, 2011

### *Regional*

- Hiding in Plain Sight: Prostate Cancer, Diagnostic Excellence, and Health Equity. UNC Physicians Statewide Learning Together: Empower Primary Care Lecture Series (virtual). February 25, 2025
- Hiding in Plain Sight: Prostate Cancer and Health Equity. UNC Physicians Network Medical Directors. Morrisville, NC. October 9, 2024
- Hiding in Plain Sight: Prostate Cancer and Health Equity. UNC Department of Family Medicine Grand Rounds, Chapel Hill, NC, August 8, 2024
- Hiding in Plain Sight: Prostate Cancer and Health Equity. UNC Department of Urology Floyd Fried Symposium on Advances in Urology, Chapel Hill, NC, June 23, 2023
- Hiding in Plain Sight: Prostate Cancer and Health Equity. UNC Department of Medicine Grand Rounds, Chapel Hill, NC, June 15, 2023
- How to Make the Right Connections. Faculty Development Lecture Series, UNC School of Medicine Department of Anesthesia, Chapel Hill, NC, March 2, 2023
- UNC Faculty Physicians: Leading in Quality and Value. UNC School of Medicine Clinical Department Chairs Retreat, Chapel Hill, NC, November 17, 2021
- Do or Do Not, There Is No Try. Overcoming the Opioid Epidemic, UNC Rex Surgery CME Conference, Raleigh, NC, September 28, 2019
- The UNC Health Care System Opioid Stewardship Initiative. UNC Rex Healthcare Nursing Leaders Conference, Raleigh, NC, June 14, 2019
- Addressing the Opioid Crisis: Ambulatory Care Leading the Change. UNC Ambulatory Nursing Conference, Chapel Hill, NC, April 27, 2019
- Deimplementation of Low-value, Potentially Harmful Care. UNC Department of Health Policy and Management, Implementation Science and Health (HPM 767) guest lecture, Chapel Hill, NC, April 16, 2019

- The UNC Healthcare System Opioid Stewardship Initiative. UNC Rex Healthcare Lunch and Learn Seminar, Raleigh, NC, April 4, 2019
- Surgeons: Gatekeepers to the Opioid Epidemic? UNC Rex Obstetrics and Gynecology Grand Rounds, Raleigh, NC, April 4, 2019
- Surgeons: Gatekeepers to the Opioid Epidemic? Institute for Healthcare Improvement (IHI) Student Interest Group, UNC Gillings School of Global Public Health, Chapel Hill, NC, December 4, 2018
- Surgeons: Gatekeepers to the Opioid Epidemic? Raleigh Academy of Medicine Fall Symposium (Keynote speaker), Raleigh, NC, November 7, 2018
- Surgeons: Gatekeepers to the Opioid Epidemic? Fried Symposium on Advances in Urology, Chapel Hill, NC, June 22, 2018
- Optimizing Post-Surgical Prescribing Practices: Challenges and Opportunities for Addressing the Opioid Crisis. North Carolina Translational and Clinical Sciences Institute Seminar on Methods in Opioid Research, Chapel Hill, NC, June 20, 2018
- Academic Progress in the UNC Department of Urology: The First Five Years. UNC Urology Department Faculty Retreat. Chapel Hill, NC, May 4, 2018
- Surgeons: Gatekeepers to the Opioid Epidemic? Sheps Center for Health Services Research Seminar, Chapel Hill, NC, March 19, 2018
- Pill Street Blues: The Opioid Crisis in North Carolina. REX Healthcare Surgery CME Conference, Raleigh, NC, March 17, 2018
- Recognizing and Dealing With Overdiagnosis in Prostate Cancer. UNC Internal Medicine Conference, Chapel Hill, NC, March 8, 2018
- Surgeons as Gatekeepers to the Opioid Epidemic. UNC Rex Healthcare Surgical Associates, Raleigh, NC, December 7, 2017
- Challenges and Opportunities for Physician-led Stewardship of Advanced Imaging in Urology. 15<sup>th</sup> Annual Fried Symposium on Advances in Urology, Chapel Hill, NC, June 23, 2017
- Hematuria Management: An Opportunity to Improve the Value of Care? GI Epidemiology Seminar, UNC School of Medicine, Chapel Hill, NC, March 2, 2016
- Twitter and the Many Uses of Tweets. UNC Department of Health Policy and Management Educational Excellence and Innovation Seminar, Chapel Hill, NC, February 20, 2015

- Superficial Bladder Cancer Update: Surveillance of Low Risk Disease. Floyd Fried Symposium on Advances in Urology, Chapel Hill, NC, June 21, 2014
- Low Risk Bladder Cancer Surveillance: A Challenge for Patient-centered Survivorship in Geriatric Oncology. Geriatric Oncology Seminar, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, June 12, 2014
- Comparative Effectiveness of Surveillance Regimens for Low Risk Bladder Cancer. Cancer Outcomes Research Program Seminar Series, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, May 13, 2014
- The Brave New World of Public Surgical Quality Reporting. Carolinas Medical Center, Charlotte, NC, December 13, 2013
- Active Surveillance for Prostate Cancer. UNC Cancer Network TeleHealth Lecture Series, Chapel Hill, NC, August 28, 2013  
<http://uncnc.mediasite.mcnc.org/mcnc/Play/9282694794d243358591a03d4823a0681d?catalog=9934f851-def7-4082-9e63-defa937c3583>
- The ABCs of Quality Reporting in Surgery. 11<sup>th</sup> Annual Landes Symposium, Chapel Hill, NC, June 21, 2013
- Contemporary Concepts in Prostate Cancer (Including Active Surveillance), UNC Internal Medicine CME Conference, Chapel Hill, NC, March 13, 2013
- UNC Urology Research: Past, Present and Future. Division of Urology Faculty Retreat, UNC School of Medicine, Chapel Hill, NC, January 11, 2013
- The population-level burden of misclassified benign renal masses. Center for Gastrointestinal Diseases Epidemiology Seminar, UNC School of Medicine, Chapel Hill, NC, December 4, 2012
- Trends in Bladder Cancer Incidence: Implications for Cancer Control Policy. Bladder Cancer Interest Group, UNC Lineberger Cancer Center, Chapel Hill, NC, November 14, 2012
- UNC Lineberger: A National Leader in Bladder Cancer. North Carolina Cancer Hospital Cancer Committee Meeting, Chapel Hill, NC, June 14, 2012.
- The Association Between Hospital Volume and 90-day Mortality After Radical Cystectomy: A Case Study in Cancer Care Quality from the National Cancer Database. Cancer Care Quality Seminar, Department of Health Policy and Management, UNC Chapel Hill, Chapel Hill, NC, April 10, 2012.

- Population-Based Clinical and Translational Epidemiology in Bladder Cancer: The UNC-Aarhus Collaboration. Center for Gastrointestinal Diseases Epidemiology Seminar, UNC School of Medicine, Chapel Hill, NC, March 14, 2012
- Treatment of Prostate Cancer—Have the Stakes Changed? Howard Holderness Distinguished Scholar Seminar Series, UNC School of Medicine, Chapel Hill, North Carolina, September 1, 2011
- Patterns of Care in Non-Muscle-Invasive Bladder Cancer: Results from the BCAN Survey. 9<sup>th</sup> Annual Landes Symposium, Chapel Hill, North Carolina, June 17, 2011
- Bladder Cancer Basics. Urology Nursing Society Southeast Regional Meeting, Chapel Hill, North Carolina, March 25, 2011
- Risk Stratification and Decision Making in Urologic Oncology. UNC Center for Gastrointestinal and Bowel Disease (CGIBD) Epidemiology Seminar, Chapel Hill, North Carolina, December 15, 2010
- Risk Stratification as a Framework for Evaluating Quality of Cancer Care. VA Health Services Research (HSR&D) Working Group, Durham, North Carolina. June 8, 2010
- Updated Prostate Cancer Surveillance Program Guidelines. Rex Cancer Center Genitourinary Oncology Journal Club, Raleigh, North Carolina. June 3, 2010.
- Cancer Decision Making: Uncertainty and Competing Risks. North Carolina State University Department of Operations Research, Raleigh, North Carolina. April 21, 2010
- Prostate Cancer Update 2010: Active Surveillance of Favorable Risk Disease. Texas Association of Genitourinary Surgeons Annual Meeting. Chapel Hill, North Carolina, April 17, 2010
- Prostate Cancer Update 2009. North Carolina Academy of Family Physicians Winter 2009 Meeting, Asheville, North Carolina, December 4, 2009
- Genitourinary trauma: Clinical issues relevant to contemporary nursing practice. Johns Hopkins Hospital Department of Nursing Trauma Continuing Education Lecture series, Baltimore, Maryland, March 20, 2008.
- A critical analysis of the interpretation of biochemical recurrence in surgically treated patients using the revised ASTRO criterion—“Nadir + 2.” The Maryland Urological Meeting, Baltimore, Maryland, November 10, 2007.

- Visiting Resident Speaker, Abraham T. Spence Visiting Professorship, University of Texas, Southwestern Medical Center, Dallas, Texas, 2006.

### **Print / Television / Radio / Social Media Engagement**

- Men's Health and Prostate Cancer Screening. Carolina Today, CBS-17, Raleigh, North Carolina, September 3, 2025
- Diagnostic Excellence in Urology: Advancing Equity and Precision in Prostate Cancer Diagnosis and Beyond. Friedlander DF\* and **Nielsen ME**, *AUA News*, February 27, 2025
- The National Urology Quality Agenda: Priorities and Strategies. **Nielsen ME**, *AUA News*, November 2024
- AQUA Registry Data Support Move to Value-Based Care in Urology. **Nielsen ME**, *American Journal of Managed Care* video interview. August 27, 2024
- The State of Urology in the US: AUA Census. Backtable Urology Podcast recorded July 18, 2024
- Collaborative Cross-Specialty Engagement to Enhance Access to Quality Urologic Care. Galansky L\* and **Nielsen ME**, *AUA News*, June 18, 2024
- The Value of the AUA Census for Urology. *Urology Times* video interview, June 6, 2024
- Tenth Anniversary of the AQUA Registry. **Nielsen ME**, *AUA News*, May 2024
- Science and Quality 2023 Year in Review. **Nielsen ME** and Kirkby E, *AUA News*, February 2024
- Diagnostic Excellence: A Conceptual Framework to Improve Quality and Equity in Urology Care. **Nielsen ME**, *AUA News*, October 2023
- 2023 Quality Improvement Summit on Telehealth. **Nielsen ME**, *AUA News*, August 2023
- AUA Science and Quality Council—Update on DEI Efforts. **Nielsen ME**, *AUA News*, June 2023
- Developing a national urologic quality strategy to support ABU Continuing Certification requirements. **Nielsen ME**, *AUA News*, February 2023
- Greetings from the new Science and Quality Council Chair. **Nielsen ME**, *AUA News*, November 2022

- Three Things to Know About Prostate Cancer. <https://healthtalk.unchealthcare.org/3-things-to-know-about-prostate-cancer/> UNC HealthTalk, September 2022
- Helping prostate cancer patients in 2022. Opening Keynote for MaleCare 2022 Prostate Cancer Patient Conference [https://youtu.be/0\\_im5CXO5kA](https://youtu.be/0_im5CXO5kA) March 3, 2022
- Incorporating alternatives to opioids for post-operative pain control in urology is more important than ever in the pandemic era. Robles J and **Nielsen ME**, *AUA News*, June 2021
- Dr. Balfour Mount: The Father of Palliative Care. The Surgical Palliative Care Podcast Interview, January 10, 2020. <https://podcasts.apple.com/us/podcast/the-surgical-palliative-care-podcast/id1492181491?i=1000462193243>
- Hematuria—should the workup include imaging? New England Journal of Medicine Journal Watch Clinical Conversations Podcast interview, August 8, 2019 <https://podcasts.jwatch.org/index.php/podcast-228-hematuria-should-the-workup-include-imaging/2019/08/08/>
- Guideline-based hematuria evaluation may up risk of secondary cancers. Renal and Urology News, July 31, 2019 <https://www.renalandurologynews.com/home/news/urology/kidney-cancer/guideline-based-hematuria-evaluation-may-up-risk-of-secondary-cancers/>
- Evaluating Hematuria: Uniform Use of CT Seen as Risky and Expensive. New England Journal of Medicine Journal Watch, July 30, 2019 <https://www.jwatch.org/fw115656/2019/07/30/evaluating-hematuria-uniform-use-ct-seen-risky-and>
- CT scans for patients with hematuria associated with harmful outcomes, increased costs. Healio Primary Care, July 29, 2019 <https://www.healio.com/internal-medicine/practice-management/news/online/%7Bfd8a115e-fd83-4058-938d-0b87daf3e955%7D/ct-scans-for-patients-with-hematuria-associated-with-harmful-outcomes-increased-costs>
- CT for Hematuria Evaluation Does More Harm Than Good. Medscape Medical News, July 30, 2019 <https://www.medscape.com/viewarticle/916194>
- Engagement with Professional Societies to Impact National Practice. *AUA News*, June 2019
- Opioid Overprescription Targeted by New Plans. Medscape, May 19, 2018. <https://www.medscape.com/viewarticle/896936>
- Opioid Stewardship in Urology. Press Program, American Urological Association Annual Meeting, San Francisco, CA, May 18, 2018

- Tradeoffs of Harm, Benefit and Cost in Hematuria Evaluation. Grand Rounds in Urology. April 2018 <https://grandroundsinurology.com/the-pros-and-cons-of-evaluating-hematuria/>
- American Urological Association AUA University Podcast, “Urology 101” June 2017 <http://www.urologyhealth.org/living-healthy/podcast/ep-19-urology-101-with-dr-matt-nielsen>
- Interview on ACP Guideline for Evaluation of Hematuria as a Marker of Occult Urinary Tract Malignancy. *New England Journal of Medicine Journal Watch Audio General Medicine*. Audio Digest International. April 1, 2016. [http://www.audiodigest.org/editorial/JW/audio/jw2707\\_2.mp3](http://www.audiodigest.org/editorial/JW/audio/jw2707_2.mp3)
- “Early Detection is Key to Fighting Prostate Cancer” WRAL-TV (local CBS affiliate) interview, November 30, 2015 <http://www.wral.com/early-detection-is-key-to-fighting-prostate-cancer/15135559/>
- “Bladder Cancer” on Sirius XM Dr. Radio Men’s Health Show, October 7, 2015
- “Active Surveillance for Prostate Cancer” Best Doctors® Global Grand Rounds, July 24, 2013 <http://www.youtube.com/watch?v=8pk0KYiBtAU&list=PLLIg0Eshhz1UAW02PjRSDNIYkeusitBI3&index=2>
- “Hematuria,” on Sirius XM Dr. Radio Men’s Health Show, March 6, 2013
- “Diagnosing Bladder Cancer: Signs, Symptoms and Tests.” Bladder Cancer Advocacy Network (BCAN) Patient Education Webinar, February 19, 2013. <http://www.bcan.org/stay-informed/patient-insight-webinars/diagnosing-bladder-cancer-signs-symptoms-tests/>
- TalkAboutHealth.com Internet Forum: Localized Prostate Cancer. January 25, 2013. <http://talkabouthealth.com/MatthewNielsenMD> 2,240 page views as of July 15, 2013.
- “New Prostate Cancer Test Advice Overturns Dogma” WRAL-TV (local ABC affiliate) live interview, October 5, 2011 <http://abclocal.go.com/wtvd/video?id=8383603&syndicate=syndicate&section>
- “Skip the PSA Test for Prostate Cancer?” *US News and World Report* interview, <http://health.usnews.com/health-news/managing-your-healthcare/cancer/articles/2010/09/15/skip-the-psa-test-for-prostate-cancer>, September 15, 2010

2014-2020      Faculty Director  
                          Digital Content and Engagement Strategy

Cancer Outcomes Research Program  
UNC Lineberger Comprehensive Cancer Center  
Chapel Hill, North Carolina

## GRANTS

### *Current:*

1R34CA286602-01A1 11/1/2024-10/31/2027  
National Cancer Institute \$882,154  
*Personalized Cancer Support for Young Adults.* (Megan Haymart, PI)  
The goal of this grant is to develop decision support and survivorship care resources for young adults with cancer diagnoses.  
*Role: UNC Site PI / Co-Investigator*

### *Completed:*

No number assigned 07/1/2024-06/30/2025  
National Academy of Medicine / Gordon and Betty Moore Foundation \$35,000  
*Advancing Diagnostic Excellence and Health Equity in Prostate Cancer Care through Enhanced Quality in MRI and MRI Fusion Biopsy*  
The goal of this grant is to convene leaders from the American Urological Association, the American College of Radiology, and regional improvement collaboratives in the U.S. focused on quality improvement in prostate MRI and targeted “MRI fusion” prostate biopsy. Activities include convening an in-person Think Tank meeting for these leaders to connect and share learnings, which will inform the development of implementation toolkits to disseminate best practices supporting the consistent and proficient execution of these critical elements of the prostate cancer diagnostic pathway.  
*Role: Principal Investigator*

No number assigned 11/1/2023-10/31/2024  
Council of Medical Specialty Societies / John Hartford Foundation \$100,000  
*Promoting Diagnostic Excellence and Health Equity in Urology Care* (Nielsen PI)  
The goal of this grant is to develop and disseminate educational resources for urologists, primary care physicians, and patients to support the dissemination of principles of Diagnostic Excellence in the care of patients with urological conditions. Particular emphasis will be applied to the opportunities to address historical inequity in outcomes for Black men with prostate cancer, alongside general educational modules.  
*Role: Principal Investigator*

W81XWH2110775 09/01/2021 – 08/31/2024  
Department of Defense \$929,618  
*Personalizing Kidney Cancer Communication to Support Patient-Centered Decision Making* (Hung-Jui Tan, PI)  
The goal of this project is to improve the decision-making experience by personalizing how patients receive information about their possible kidney cancer. By defining, building, and testing

personalized communication for patients with early-stage kidney cancer, we hypothesize that personalized communication responsive to the specific communication and support needs of patients will improve the perceived quality of communication, thus improving the decision-making experience.

*Role: Co-Investigator*

Q125EP20 11/01/2019 – 10/31/2024

University of Kansas Medical Center (PI: Nielsen) \$92,599

*North Carolina Prospective Prostate Cancer Cohort Study*

The goals of this project include continued data collection (annual follow-up surveys and medical records) for the NC ProCESS study for up to 10 years of follow-up on all enrolled study participants.

*Role: Principal Investigator*

1R01CA2-4193 4/1/2019-3/30/2024

National Cancer Institute \$3,254,226

*Ostomy Telehealth Self-Management Training for Cancer Survivors* (Robert Krouse, PI)

Implementation and evaluation of telehealth self-management intervention for patients with ostomies living in rural communities

*Role: Co-investigator, UNC Site PI*

MRS-18-193-01-CPPB 01/01/2019 – 12/31/2023

American Cancer Society \$737,000

*Designing Visual Tools to Enhance Cancer Surgeon Decision-Making* (Hung-Jui Tan, PI)

The primary objective of this study is to design and develop a health IT-based tool that is usable and impacts cancer care. The specific aims are to 1) determine whether health IT behavior influences how urologists make decisions for cancer, 2) evaluate the effect of information visualization on surgeon risk perception and judgment, and 3) assess prospectively the impact of visual decision support on surgeon risk communication in clinic

*Role: Mentor*

No number assigned 08/15/2021-08/31/2023

American Urological Association \$80,000

*Improving pathways of care for renal colic as a means to address low-value services* (David Friedlander, PI)

Provide a comprehensive portrait of risk-adjusted pathways of care for individuals presenting with acute renal colic in order to identify low-value services. This will be achieved by utilizing a multi-level mixed-methods approach and consists of two stages: 1) use Medicaid and private-payer claims data sources to conduct polynomial regression as a means to define the clinical period surrounding a diagnosis of acute renal colic and identify factors associated with the largest variation in daily episode-specific spend. After defining this period we will then 2) conduct semi-structured interviews and surveys among patients and providers to ascertain clinical and non-clinical drivers of variation in episode-specific spend.

*Role: Mentor*

1R01LM013329 9/10/2019 - 7/31/2023

National Science Foundation/NIH Connected Health \$135,720

*AURA: Connecting Audio and Radio Sensing Systems to Improve Care at Home* (Nirjon & Song, MPI)

This study aims to develop and pilot test the AURA system of symptom and complication monitoring and management for cancer patients and their caregivers in home settings.

*Role: Co-investigator*

1R01NR016990-01A1

9/25/2017-6/30/2022

National Institute of Nursing Research

\$2,583,736

*Efficacy of a Couple-focused, Tailored, Symptom Self-management mHealth Intervention for Prostate Cancer and Their Partners* (Lixin Song, PI)

Implement and test efficacy of a tailored dyadic symptom management mHealth intervention in a diverse population of men and partners with newly diagnosed prostate cancer

*Role: Co-investigator*

W81XWH1910512

11/03/2019 – 07/31/2022

Department of Defense

\$713,426

*Long-Term Outcomes of Localized Prostate Cancer Survivors* (Ron Chen, PI)

Study long-term (8-10 year) outcomes of patients enrolled in the NC ProCESS cohort (cohort of men enrolled from 2011-2013 who were newly-diagnosed with prostate cancer) by creating a unique and comprehensive data set that includes quality of life, insurance claims data, and cancer registry data. This includes long-term urinary, bowel and sexual quality of life after active surveillance, surgery, or radiation; medical procedures or hospitalizations due to treatment-related complications; cancer control/recurrence; and overall survival.

*Role: Co-investigator, UNC Site PI*

Pilot Award # TSM PAR61803

7/1/2018-6/30/2019

North Carolina Clinical and Translational Science Award (CTSA)

\$49,986

*The Opioid Data Research Hub: A New Approach for Data Linkage*

Develop and evaluate algorithms to link insurance claims, electronic medical record, and publicly available datasets to support investigations related to factors associated with the development of new chronic use of opioids after surgical procedures

*Role: Principal Investigator*

Campus Innovation Grant

7/1/2018-6/30/2019

North Carolina Area Health Education Centers (AHEC)

\$43,398

*Enhancing Interdisciplinary Opioid Stewardship: Education and Training to Mitigate Postoperative Risk*

Develop interprofessional education materials and community resources supporting stewardship of prescription opioid medications after procedural care. The work leverages interdisciplinary expertise from the UNC Schools of Medicine, Pharmacy, Nursing, Social Work and Dentistry to mitigate harms of opioids from the patient safety and public health perspectives.

*Role: Co-Principal Investigator with Kimberly Sanders*

1503-29220

2/01/16-1/31/19

Patient-Centered Outcomes Research Institute

\$1,712,057

*Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors* (Ron Chen, PI)

Utilizing large population-based datasets of prostate cancer survivors, this project will seek to characterize the effectiveness of post-treatment surveillance and illuminate strategies for patient-centered survivorship care

*Role: Co-investigator (10% effort)*

1R13HS026679-01

9/1/2018-8/31/2019

Agency for Healthcare Research and Quality

\$35,100

*American Urological Association's Quality Improvement Summit: Opioid Stewardship in Urology* (Angela Smith, PI)

Multidisciplinary conference convening stakeholders from the American Urological Association, general surgery, and anesthesia/pain management communities around opportunities for collaborative patient safety / quality improvement work around the utilization of opioids for patients with urological conditions

*Role: Chair-elect, AUA Quality Improvement and Patient Safety Committee*

Pilot Award # SE1605

6/21/2018-12/21/2018

North Carolina Clinical and Translational Science Award (CTSA)

\$1,800

*Right-sizing Post-operative Prescribing for Opioid Naïve Patients—A Stakeholder Guided and Team-based Approach to Mitigating Chronic Opioid Use*

Engage multidisciplinary stakeholders across the continuum of care to identify and prioritize study design and trial outcome decisions for planned multicenter precision medicine trial of postoperative opioid prescribing

*Role: Co-Principal Investigator with Jacquie Halladay*

1R21CA212516-01

12/1/2016-11/30/2018

National Cancer Institute

\$363,660

*Enhancing Survivorship Care Planning for Patients with Localized Prostate Cancer Using a Couple-focused Web-based Tailored Symptom Self-management Program* (Lixin Song, PI)

Implement and refine a novel electronic tailored symptom management intervention targeted at patient/partner dyads in the context of newly diagnosed localized prostate cancer

*Role: Co-investigator (1% effort)*

Collaborative Pilot Grant (no number)

7/1/2017-6/30/2018

Patient Outcomes Research To Advance Learning (PORTAL) Network

\$117,050

Patient-Centered Outcomes Research Institute

*Implementation and Dissemination of Novel Approaches to Hematuria Evaluation* (Sheila Weinmann, PI)

Develop and validate computable phenotypes to identify episodes of care for hematuria evaluation, procedural and imaging components of these episodes, and outcomes attributable to these episodes. This work will provide preliminary data for planned future proposals examining alternative approaches to hematuria evaluation in a diverse array of US health systems

*Role: Co-investigator (10% effort, in kind)*

5R21CA191610-02 Revised (Disparities Supplement)

8/31/16-9/1/17

National Cancer Institute

\$143,884

*Optimizing Risk Stratification to Manage Early Stage Bladder Cancer*

This supplement builds on the parent grant, adding data from Geisinger Health System to the Kaiser Permanente Northwest cohort in Aim 1 of the parent grant, with additional analyses investigating sex disparities in the combined dataset

*Role: Co-Principal Investigator with Carmit McMullen*

NIH Health Care Systems Research Network / Older Americans Independence Centers  
AGING Initiative Pilot Project 11/2016-10/2017

*Multiple Chronic Conditions and Mortality in Older Adults with Superficial Bladder Cancer* [Tullika Garg (mentee), PI] \$40,000

This project aims to characterize the interplay between multiple chronic conditions, including early stage bladder cancer, and mortality in the older adult population

*Role: Mentor/Co-Investigator (2% effort, in kind)*

1R21CA191610-01 1/1/15-12/31/17  
National Cancer Institute \$461,376

*Optimizing Risk Stratification to Manage Early Stage Bladder Cancer*

Development and validation of a risk calculator predicting disease recurrence and progression from a population-based community-dwelling cohort of patients with superficial bladder cancer in Kaiser Permanente Northwest; design and implementation of a point-of-care decision support intervention with the risk calculator

*Role: co-Principal Investigator, with Carmit McMullen (10% effort)*

1R13HS025664-01 10/21/2017  
Agency for Healthcare Research and Quality \$24,950

*Challenges and Opportunities for Stewardship of Urological Imaging*

Multidisciplinary conference convening stakeholders from the American Urological Association, American College of Emergency Physicians, and American College of Radiology around opportunities for collaborative patient safety / quality improvement work around the utilization of advanced imaging for patients with urological conditions

*Role: Principal Investigator / Conference Chair*

Geisinger Scientific Review Committee Small Grant Award 6/2016-5/2017

*Patient-centered Outcomes in Elders with Superficial Bladder Cancer and Multiple Chronic Conditions* [Tullika Garg (mentee), PI] \$19,953

Utilizing a large dataset of patients from an integrated delivery system, this project seeks to characterize patient-centered outcomes in older adults with early stage bladder cancer and multiple chronic conditions

*Role: Mentor/Co-Investigator (5% effort, in kind)*

PCORI Engagement Award 12/01/14-12/01/16  
Knowledge Award \$121,237

*Bladder Cancer Patient Survey Network for Research Prioritization* (Angela Smith, PI)

This knowledge award involves development of a survey network of bladder cancer patients by engaging patients and caregivers involved with Bladder Cancer Advocacy Network and conduct research prioritization activities. In this project, we aim to recruit users to participate in the Patient

Survey Network, generate research questions, and prioritize research questions with the ultimate goal to create a sustainable method for conducting research prioritization with bladder cancer patients on an iterative and ongoing basis

*Role: co-investigator*

Rising Stars in Urology Research Award (not assigned) 8/1/13-6/30/16  
Urology Care Foundation and Astellas Pharma, US \$101,000

*Awarded in recognition of Optimizing Survivorship and Decision Making in Low Risk Bladder Cancer*

*Role: Principal Investigator*

Mentored Research Scholar Grant MRSRG-13-154-01-CPPB 7/1/13-6/30/16  
American Cancer Society \$437,000

*Optimizing Survivorship and Decision Making in Low Risk Bladder Cancer*

60% effort

Mentors: M. Pignone, E. Myers, A. Zauber, B. Hauber, B. Denton, R. Pruthi

Development of microsimulation model of the natural history of low risk bladder cancer and measurement of utilities and patient preferences related to treatment alternatives

*Role: Principal Investigator*

Concept Grant (no number; David Johnson, PI/mentee) 7/1/15-6/30/16  
Society of Urology Chairs and Program Directors \$24,000

*An Open-access Resource to Address Unmet GME Needs Related to Quality Improvement Activities*

Development of a web-based educational resource for urology residents, department chairs, and residency program directors cataloguing available resources to support quality improvement education

*Role: Mentor/Faculty Sponsor; Co-Investigator*

UNC Lineberger Developmental Award (not assigned) 7/1/14-6/30/15  
University of North Carolina Lineberger Comprehensive Cancer Center \$50,000

*MISCAN-Bladder: A Simulation Model for Comparative Effectiveness Research*

Development of a population-based simulation model of superficial bladder cancer using the established MISCAN architecture with collaborators from Erasmus MC, Rotterdam, The Netherlands

*Role: Principal Investigator*

HMO Cancer Research Network Pilot Award CRN14012 7/1/14-6/30/15  
HMO Cancer Research Network U24 CA171524 \$75,000

*Optimizing Risk Stratification to Manage Early Stage Bladder Cancer*

5% effort

[Funded and withdrawn due to overlap with 1R21CA191610-01, above]

Development and validation of a risk calculator predicting disease recurrence and progression from a population-based community-dwelling cohort of patients with superficial bladder cancer in Kaiser Permanente Northwest

*Role: Principal Investigator*

HMO Cancer Research Network (CRN) Pilot Award CRN14016	7/1/14-6/30/15
HMO CRN U24 CA171524 (Ramzi Salloum, PI, <u>mentee</u> )	\$75,000
<i>Patterns of Care and the Diffusion of New Technologies in Prostate Cancer</i>	
5% effort	
The objectives of this study are to understand the determinants and cost implications of prostate cancer patterns of care and diffusion of new technologies across diverse patient populations and health care markets	
<i>Role: co-Investigator</i>	
University Cancer Research Fund (UCRF) Innovation Award	7/1/13-6/30/15
UNC Lineberger Comprehensive Cancer Center (Ron Chen, PI)	\$175,000
<i>Building and characterizing the North Carolina Bladder Cancer Cohort: Defining Quality of Life and Potential Health Care Needs During Survivorship</i>	
5% effort (in kind)	
This project will leverage the North Carolina Central Cancer Registry's Rapid Case Ascertainment program to develop a population-based cohort of patients newly diagnosed with bladder cancer in the state of North Carolina. The focus of the study will be on quality of life and receipt of recommended primary/preventive care services after a diagnosis of bladder cancer.	
<i>Role: co-investigator</i>	
Population Sciences Developmental Research Award (not assigned)	7/1/13-6/30/14
UNC Lineberger Comprehensive Cancer Center (Lixin Song, PI)	\$35,000
<i>Development of a Couple-focused eHealth Intervention for Prostate Cancer-Related Symptom Management</i>	
5% effort (in kind)	
This project adapted content from a proven in-person symptom management program into an eHealth application for use by prostate cancer survivors and their partners	
<i>Role: co-investigator</i>	
AHRQ Recovery Act (ARRA) Grant 1R18AE000023-01	9/1/10-8/1/13
Agency for Healthcare Research and Quality	\$2,902,667
C. Lewis (UNC) and D. Frosch (Palo Alto Medical Research Foundation) (co-PIs)	
<i>Accelerating Adoption of CER Results With Patient Decision Support Interventions</i>	
5% effort (in kind during period of KL2 support)	
Randomized trials of decision support interventions surrounding decisions to undergo PSA screening (study 1) and treatment decision-making for men diagnosed with low risk clinically localized prostate cancer (study 2)	
<i>Role: Lead investigator for Study 2 at UNC site</i>	
AHRQ HHSA29020050040I	9/16/05-7/14/13
Agency for Healthcare Research and Quality (Paul Godley, PI)	\$623,543
<i>Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network</i>	
10% effort (in kind during period of KL2 support)	
This project used secondary analysis of existing data, retrospective analysis of SEER/Medicare data and prospective cohort data to comparative the effectiveness of management options for early prostate cancer.	

*Role: Co-Investigator (2009-2013)*

UNC Clinical Translation Science Award (CTSA) Marshall Runge (PI) 5/19/08-4/30/13  
K12 Scholars Program (KL2) NIH/NCRR 1KL2RR025746 \$2,090,864 (Direct)  
*Risk-Treatment Mismatch and Decision Making in Urologic Oncology*  
50% effort

A national consortium with the goal of transforming how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients.

*Role: KL2 Scholar(supported 4/1/09-3/30/12)*

Trainee Mini-grant George Netto (co-PI) 7/1/06-6/30/07  
National Kidney Foundation of Maryland \$10,000  
*Biomarkers of Recurrent and Lethal Bladder Cancer in Primary Cystectomy Tissue*  
20% effort (no salary support)

This project supported the construction of a bladder cancer tissue microarray of cystectomy specimens from patients who developed metastasis and / or bladder cancer-specific mortality after cystectomy alongside recurrence-free cases, creating a resource to facilitate the evaluation of candidate biomarkers.

*Role: Co-investigator*

Professional Development Award Soner Altioek (co-PI) 7/1/06-6/30/07  
National Kidney Foundation of Maryland \$40,000  
*Prediction and Assessment of Response to Targeted Therapy in Bladder Cancer*  
20% effort (no salary support)

The primary goal of this study was the evaluation of a panel of small-molecule tyrosine kinase inhibitors targeting signaling pathways implicated in the pathogenesis of bladder cancer. The ultimate goal of the project was to identify potential novel therapeutic agents for bladder cancer as well as to develop and characterize candidate biomarkers to guide treatment selection in individual patients

*Role: Co-investigator*

Kirchstein National Research Service Award Don Coffey (PI) 7/1/05-6/30/06  
National Institutes of Health grant # T32-DK007552-19 \$43,428  
*Clinical and translational research in urologic oncology*  
100% effort / 100% salary support

This grant supported the first 12 of 18 months of dedicated full-time work on clinical and translational research in urologic oncology under the mentorship of senior investigators in the department of Urology and affiliated departments and divisions within the Johns Hopkins Medical Institutions.

*Role: Research fellow*

## **TEACHING RECORD**

### **Course Director**

- “The Art of Medicine.” HNRS 350 Honors Carolina Undergraduate Seminar, The University of North Carolina at Chapel Hill Undergraduate Honors Program. 1.0 credit hours, spring semester, 2023-present
- Course Director, Landes Symposium on Advances in Urology, University of North Carolina Continuing Medical Education Programs, 2011

### **Lecture / Classroom instruction:**

- Hiding in Plain Sight: Prostate Cancer, Diagnostic Excellence, and Health Equity. UNC Department of Medicine Resident Teaching Conference. September 8, 2025
- Relational Leadership in Healthcare, Panelist, Interprofessional Excellence Ideas, Information, and Inquiry (“Triple I”) seminar (course director: Meg Zomorodi, PhD, Associate Provost for Interprofessional Education, UNC Chapel Hill), October 1, 2024
- High Value Care: How Do We Get There? Value-Based Care Lecture Series, UNC School of Medicine, Chapel Hill, NC, April 30, 2020
- Lessons Learned in Crisis Leadership. In: Smithson S, Foster J, Bogdewic S (directors). Medical Management of COVID-19 Course: UNC School of Medicine & North Carolina AHEC. Available at Association for American Medical Colleges iCollaborative (<https://icollaborative.aamc.org/resource/5110/>), UNC School of Medicine, Chapel Hill, NC, April 16, 2020
- High Value Care: How Do We Get There? UNC School of Medicine Population Health Lecture Series, Chapel Hill, NC, June 18, 2019
- Deimplementation of Low-value, Potentially Harmful Care. UNC Department of Health Policy and Management, Implementation Science and Health (HPM 767) guest lecture, Chapel Hill, NC, April 16, 2019
- TeamSTEPPS / Leadership Development. UNC Schools of Medicine and Nursing, Clinician Leadership in Quality and Safety Scholarly Concentration; 2018-2023
- Optimizing Risk Stratification and Decision Making in Superficial Bladder Cancer: A Case Study of Surveillance (annual). Cancer Survivorship, Epidemiology and Outcomes course (EPID 771, guest lecturer), Department of Epidemiology, UNC Gillings School of Global Public Health, 2015-2022
- Management of Bladder Cancer (annual). UNC Chapel Hill Radiation Oncology Residency Program, 2012-2017

- Urologic Oncology lecture (quarterly), UNC Chapel Hill School of Medicine Third Year Surgery Clerkship, 2009-2016
- Urology for General Surgeons (annual). UNC Chapel Hill General Surgery Residency Program, 2012-2014
- Epidemiology of Renal Cell Carcinoma. Advanced Cancer Epidemiology Seminar, Department of Epidemiology, UNC Gillings School of Global Public Health, April 17, 2013
- Prostate Diseases Lecture (annual). UNC Chapel Hill School of Medicine 2<sup>nd</sup> year Curriculum, 2009-2013
- Gross Anatomy Dissection for Outgoing UNC Chapel Hill Medical Students in Urology (annual). UNC Chapel Hill School of Medicine Capstone Program, 2009-2012
- Director of Weekly Urology Resident / Student Didactic Lecture Series, Johns Hopkins Hospital Brady Urological Institute; 2008
- Johns Hopkins University School of Medicine Freshman Histology, Laboratory Teaching Assistant, 2002

### **Grand Rounds**

- Surgeons as Gatekeepers to the Opioid Epidemic. Department of Orthopaedic Surgery Grand Rounds, UNC School of Medicine, Chapel Hill, NC, December 11, 2017
- Prostate Cancer: What's New in 2017? Department of Medicine Grand Rounds, UNC School of Medicine, Chapel Hill, NC, April 27, 2017
- Hematuria Evaluation: An Opportunity to Enhance Value? Department of Urology Grand Rounds, UNC School of Medicine, Chapel Hill, NC, November 4, 2015
- Optimizing Survivorship and Decision Making in Low Risk Bladder Cancer. Division of Urology Grand Rounds, Washington University School of Medicine, St. Louis, Missouri, June 3, 2015
- Examining the Value of Different Approaches to the Patient with Hematuria. Department of Urology Grand Rounds, UNC School of Medicine, Chapel Hill, NC, October 8, 2014
- Social Media as a Platform for Professional Development in Academic Medicine. Department of Urology Grand Rounds, UNC School of Medicine, Chapel Hill, NC, December 11, 2013

- Public Reporting of Surgical Quality: The Brave New World. Department of Surgery Grand Rounds, UNC School of Medicine, Chapel Hill, NC, October 2, 2013
- The ABCs of Quality Reporting in Surgery. Division of Urology Grand Rounds, UNC School of Medicine, Chapel Hill, NC, December 4, 2012
- Active Surveillance for Prostate Cancer. Division of Urology Grand Rounds, UNC School of Medicine, Chapel Hill, NC, July 11, 2012
- Renal Cell Carcinoma 2009: Challenges and Opportunities. Department of Surgery Grand Rounds, UNC School of Medicine, Chapel Hill, NC, March 18, 2009
- Bladder Cancer Research: Opportunities for Discovery. Vattikuti Urological Institute Grand Rounds, Henry Ford Hospital, Detroit, Michigan. October 19, 2007.

*Brady Urological Institute Grand Rounds(Category I CME)  
Johns Hopkins Medical Institutions, Baltimore, Maryland:*

- February 2008: Management of Neurogenic Bowel in Spina Bifida
- August 2007: Gleason Grade Discordance from Biopsy to Prostatectomy
- March 2007: Targeting Targeted Therapy in Bladder Cancer
- December 2006: Traumatic Injuries to Male Genitalia
- August 2006: Patient Age and Bladder Cancer Outcomes
- March 2006:Urinary Markers for Bladder Cancer Detection
- July 2005: Management of Ureteral Tumors
- March 2005: Genitourinary Tuberculosis
- October 2004: Adrenocortical Carcinoma
- September 2004: Ejaculatory Duct Obstruction
- August 2004: Incidentally Detected Adrenal Masses
- March 2004: Cytoreductive Nephrectomy

**Research mentorship (*Mentee honors and awards in bold*)**

- Extramural Junior Faculty
  - Deborah Kaye, Assistant Professor of Urology and Population Sciences, Duke University, 2019-present
  - Kara Watts, Assistant Professor of Urology, Albert Einstein School of Medicine / Montefiore Medical Center, 2019-present
  - Greg Aufferberg, Assistant Professor of Urology, Northwestern University, 2018-2021
  - Jennifer Robles, Assistant Professor of Urology, Vanderbilt University, 2018-present
  - Lindsey Herrell, Assistant Professor of Urology, University of Michigan, 2018-present

- Justin Ziemba, Assistant Professor of Surgery/Urology, University of Pennsylvania, 2017-present **AUA Data Grant Awardee, Co-chair AUA Imaging Stewardship Workgroup**
- Casey Ng, Staff Urologist, Kaiser Permanente Southern California, 2017-2021
- Tullika Garg, Clinician-Investigator, Geisinger Health System, **Surgical Outcomes Club Zinner Health Services Research Fellow, National Institute on Aging Butler-Williams Scholar**, 2015-present
- Ramzi Salloum, Assistant Professor of Health Policy, University of Florida, **NCI Cancer Research Network CRN Scholar**, 2014-2017
- UNC Junior Faculty (current position):
  - Clayton Commander, Assistant Professor of Radiology, 2022-2023
  - Shekinah Elmore, Assistant Professor of Radiation Oncology, 2022-2024
  - David Friedlander, Assistant Professor of Urology, **AUA/Urology Care Foundation Young Investigator Awardee**, 2021-present
  - Katherine Chan, Associate Professor of Urology, **NIDDK K23 Awardee**, 2021-2024
  - Gita Mody, Assistant Professor of Surgery, **NHLBI K23 awardee, 2022-2027**, 2018-2023 (Associate Professor with Tenure, UNC)
  - Nicole Chaumont, Assistant Professor of Surgery, 2018-2020 (Director of Patient Safety and Quality Improvement, Medstar Health, Baltimore MD)
  - Emily Chang, Assistant Professor of Medicine, 2017-2023 (Associate Professor of Medicine, UNC)
  - Hung-Jui Tan, Assistant Professor of Urology, 2016-2022 **American Cancer Society Mentored Research Scholar Grant awardee, 2018-2023** (Associate Professor with Tenure and Director of Urologic Oncology, UNC)
  - Adewole Adamson, Assistant Professor of Dermatology, 2015-2018 (Assistant Professor, University of Texas Dell Medical School)
  - Angela Smith, Assistant Professor of Urology, **UNC Hettleman Scholar, AUA Gold Cystoscope Award, UNC Lineberger Cancer Center John William Pope Clinical Fellow Award, 2012; KL2 Scholar; AHRQ K08 Awardee 2012-2015** (Professor with tenure and Senior Associate Dean for Faculty Affairs and Leadership Development, UNC)
  - Lixin Song, Assistant Professor of Nursing, **BIRCWH/KL2 scholar**, 2012-2014 (Professor, University of Texas San Antonio)
- Residents (current position):
  - Yousef Abu-Salha 2020-2023 (Urology practice, Raleigh, NC)
  - Mark Ehlers 2018-2021 (Urology practice, Milwaukee, WI)
  - Kathryn Hacker Gessner 2017-present (Assistant Professor of Urology, UNC)
  - Christopher Wallis 2017-present (Assistant Professor of Urology, University of Toronto)
  - David Johnson 2012-2016; **2014 UNC Lineberger Cancer Center John William Pope Clinical Fellow Award and the 2016 British Journal of Urology Coffey-**

- Krane Prize** (Associate Professor, UNC; Medical Director, Healthcare Strategy and Payment Transformation, Blue Cross Blue Shield of North Carolina)
- Will Kirby 2012-2013, **Owen Wangensteen Prize for Best Presentation in Urology Surgical Forum, American College of Surgeons Clinical Congress, 2013** (Urology practice, Wilmington, NC)
  - Angela Smith 2011-2012 (Professor with Tenure, UNC)
  - Ian Udell 2011, **Owen Wangensteen Prize for Best Presentation in Urology Surgical Forum, American College of Surgeons Clinical Congress, 2012** (UNC Urology Adjunct Faculty, Raleigh, NC)
  - Raj Kurpad 2011 (Urology practice, Dover, DE)
  - Jeffrey Nix 2009 (Professor, University of Alabama-Birmingham)
  - Ashley Ross 2008 (Associate Professor and Director of Urologic Oncology, Northwestern, Chicago, IL)
  - David Hernandez 2005-2006 (Associate Professor, University of South Florida)
- Research Fellows (current position):
    - Jacob Stein, MD, UNC Hematology/Oncology Fellow, **ASCO Conquer Cancer Young Investigator Award, 2021-2023**
    - Ahrang Jung, PhD, 2018-present (Assistant Professor, UNC Greensboro)
    - Lisa Spees, PhD, 2018-2020 (Assistant Professor of Health Policy and Management, UNC Gillings School of Global Public Health)
    - Zachary Klaassen, MD, 2017-2019 (Assistant Professor, Medical College of Georgia)
    - Devon Check, PhD, 2018-2020 (Assistant Professor, Duke Department of Population Health Sciences)
    - Jed Ferguson, MD PhD, 2010-11 (Assistant Professor, University of Alabama at Birmingham)
    - Ankur Manvar, MD, 2010-11 (Anesthesiology/Pain Medicine practice, Kings Mountain, NC)
    - Michael Muntener, MD, 2005-2006 (Chief of Urology, Triemli Hospital, Zurich, Switzerland)
  - Medical Students (current position):
    - Charan Mohan 2019 (Urology resident, Northwell Health, New York)
    - Nancy Wang 2013, **Urology Care Foundation Charles Brendler Summer Research Award** (Urology resident, Stanford)
    - A.J. Davidiuk 2011 (Urology practice, Orlando, FL)
    - Megan Feng 2011 **National Institute of Aging MSTAR Scholar** (Family Medicine practice, Monroe, MI)
    - Jeremy Reese 2009, (Urology practice, Golden, CO)
    - Marisa Meyer 2008 (Assistant Professor, Johns Hopkins)
    - Ina Wu 2005-2006 (Assistant Professor, University of Nebraska)

Graduate Student Supervision: [current position]

- Elizabeth Garry, PhD Candidate, Epidemiology, UNC Gillings School of Global Public Health, 2017-2019 (Dissertation Committee Member) [Principal Scientist, Aetion, Boston, MA]
- Mihaela Georgieva, PhD Candidate, Health Policy and Management, UNC Gillings School of Global Public Health, 2015-2019 (Dissertation Committee Member) **Horton-Hallowell Wellesley College Alumna Graduate Fellowship Award, 2017** [Health Economist and Decision Scientist, The Analysis Group, Boston, MA]
- Ahrang Jung, PhD Candidate, Nursing, UNC School of Nursing, 2015-2018 (Dissertation committee member) [Assistant Professor, UNC Greensboro]
- Saira Khan, PhD Candidate, Epidemiology, 5T32CA009330 (Cancer Epidemiology Training Grant), UNC Gillings School of Global Public Health, 2014-2016 (Dissertation committee member) [Assistant Professor of Surgery, Washington University of St. Louis]
- Sarah Lewis, PhD Candidate, Health Policy and Management, Bristol-Myers Squibb Global Health Economics and Outcomes Research Pre-doctoral Fellow, UNC Gillings School of Global Public Health, 2013-2016 (Dissertation committee member) [Center for Medicare and Medicaid Innovation (CMMI) Research and Rapid Cycle Evaluation Group, lead for VBI Medicare Advantage Model and Radiation Oncology model]
- Christine Barnett, PhD Candidate, Industrial and Operations Engineering, University of Michigan College of Engineering, 2012-2016 (co-mentor for **National Science Foundation Graduate Research Fellowship Award** with Brian Denton, PhD) [Senior Research Scientist, RTI International]
- Samira Brooks, PhD Candidate, Program in Translational Medicine, Howard Hughes Medical Institute / UNC School of Medicine, 2011-2015 (Dissertation committee member) [Senior Scientist, Amgen]
- Anne Butler, PhD Candidate, Epidemiology, 5T32CA009330-30, 2T32 DK007750-15, UNC Gillings School of Public Health, 2012-2014 (Dissertation committee member) [Assistant Professor of Medicine / Infectious Diseases, Washington University in St. Louis]
- Shellie Ellis, PhD Candidate (**Recipient of the Marci Kramish Campbell Dissertation Award**), Cancer Care Quality Training Program, Health Policy and Management, 1R25CA116339, UNC Gillings School of Public Health, 2011-2014 (Dissertation committee member) [Assistant Professor of Health Policy, University of Kansas Medical Center]
- Laurel Clayton, PhD Candidate, Cancer Care Quality Training Program, Health Policy and Management, 1R25CA116339, UNC Gillings School of Public Health, 2009-2012 (Dissertation committee member) [Senior Research Scientist, Aledade, Inc]
- Yuan Zhang, PhD Candidate, Industrial Engineering and Operations Research, North Carolina State University, 2009-2011 [Analyst, Bank of America]
- Josip Vukina, MPH thesis advisor, UNC Gillings School of Public Health, 2010-2011 [Assistant Professor of Urology, University of Pittsburgh]
- Wei-Shi Yeh, PhD dissertation advisor, Cancer Care Quality Training Program, Health Policy and Management, UNC Gillings School of Public Health, 2009-2010 [Health Economist, Genentech]

2016-present    Faculty Preceptor  
                                  Cancer Control Education Program (Kurt Ribisl, PI)

National Institutes of Health Grant R25CA057726  
UNC Lineberger Comprehensive Cancer Center  
Chapel Hill, North Carolina

2013-2019      Research Mentor / Program Faculty  
Trauma Training Grant (Bruce Cairns, PI)  
National Institutes of Health Grant T32GM008450-21  
Department of Surgery  
UNC Chapel Hill School of Medicine  
Chapel Hill, North Carolina

2009-present      Research Mentor / Program Faculty  
Cancer Care Quality Training Program (Ethan Basch, PI)  
National Institutes of Health Grant 1R25CA116339  
Department of Health Policy and Management  
UNC Chapel Hill Gillings School of Global Public Health  
Chapel Hill, North Carolina

### **Community Education / Outreach**

- Hiding in Plain Sight: Prostate Cancer and Health Equity (keynote). Men's Health Summit, Corinth AME Zion Church, Siler City, NC, June 28, 2025
- Diagnostic Excellence in the Early Detection of Prostate Cancer Among Black Men: Guidelines Updates. 50 Hoops Prostate Cancer 101 Luncheon Lecture Series, Durham, NC, June 1, 2024
- Are Surgeons Gatekeepers to the Opioid Epidemic? Solterra Community Seminar, Durham, NC, March 23, 2018
- The UNC Genitourinary Oncology Program: Multidisciplinary Research and Clinical Care. UNC Lineberger Cancer Center Board of Visitors, Chapel Hill, NC, April 7, 2017
- Kidney Cancer: Overview. North Carolina Kidney Cancer Association Patient Forum, Chapel Hill, NC, December 12, 2015
- What's New in Cancer? The Rotary Club of Winston-Salem, North Carolina, April 15, 2014
- What's New in Cancer? The Rotary Club of Sanford, North Carolina, August 13, 2013
- Exceptional: The UNC Lineberger Comprehensive Cancer Center. Kiwanis Club, Rocky Mount, North Carolina, May 30, 2013.

- Bladder Cancer Detection: Signs, Symptoms and Tests. Bladder Cancer Advocacy Network Patient Insight Webinar. <http://www.bcan.org/stay-informed/patient-insight-webinars/diagnosing-bladder-cancer-signs-symptoms-tests/> February 19, 2013
- Prostate Cancer Update 2012: PSA Screening, Racial Disparities and Multidisciplinary Care. Men's Roundtable, Gateway Convention Center, Rocky Mount, North Carolina, March 10, 2012
- Prostate Cancer Update. Wakefield Rotary International, Wake Forest, North Carolina, October 14, 2010
- Genitourinary Oncology: Prostate, Bladder and Kidney Cancer. Orange County Senior Center, Hillsborough, North Carolina, September 15, 2010
- PSA and Prostate Cancer Update: 2010. Chapel Hill Senior Center "Meet the Expert" Lecture Series, Chapel Hill, North Carolina, September 1, 2010
- Who Is and Who Is Not a Candidate for Active Surveillance (Keynote lecture). Living With and Beyond Cancer Series, Rex/UNC Healthcare, Raleigh, North Carolina. June 12, 2010
- Bladder Cancer Basics: Diagnosis and Detection. Bladder Cancer Advocacy Network Patient Forum, Chapel Hill, North Carolina. May 15, 2010
- What's New at UNC Chapel Hill Urology: New Techniques for Nerve-Sparing Open Prostatectomy and the Hopkins Active Surveillance Protocol. Lee County Prostate Cancer Support Group, Sanford, North Carolina, March 10, 2009
- Active Surveillance for Prostate Cancer and the Multidisciplinary Team Approach at the Lineberger Cancer Center. Chapel Hill Prostate Cancer Support Group, Chapel Hill, North Carolina, February 27, 2010

## **CLINICAL ACTIVITIES**

### **Certification**

- North Carolina State Medical Board, 2008-present
- American Board of Urology: Diplomate #17132
  - Initial certification 2011
  - Life Long Learning Level 2 recertification 2019 (expires 2031)
- Advanced Training Program in Healthcare Delivery Improvement (accelerated course), Intermountain Healthcare Delivery Institute, 2019
- Institute for Healthcare Improvement Coursework:
  - Leadership and Organizing for Change, 2019

- IHI Open School Improvement Capability, Patient Safety, Leadership modules
- Lean Six Sigma Yellow Belt (2012); Blue Belt (2013). Institute for Process, Leadership and Quality Improvement
- Maryland State Board of Physicians, 2006-2009
- Intuitive Surgical daVinci Robot Certification 11/17/2005

#### **Attending on Clinical Service:**

- Assistant Chief of Service (Attending for Urology Consult Service) 7/08-12/08  
Johns Hopkins Hospital, Baltimore, Maryland
- Assistant Professor of Surgery / Urology, UNC Chapel Hill School of Medicine 1/09-4/15
- Associate Professor of Urology, UNC Chapel Hill School of Medicine, 4/15-4/20
- Professor of Urology, UNC Chapel Hill School of Medicine, 2020-present

#### **Leadership Development Courses**

- Program for Chairs of Clinical Services, Harvard T.H. Chan School of Public Health Executive and Continuing Professional Education. Boston, MA. January 22-February 3, 2023
- Leader As Coach Training, Pyramid Resource Group, October-November 2022
- UNC School of Medicine Office of Inclusive Excellence Diversity, Equity, and Inclusion (DEI) Certificate Program
  - Black Surgeons and Surgery in America. Multidisciplinary Grand Rounds, April 20, 2022
  - Scholarship Addressing the Dual Pandemic of Racism and COVID-19. Race, Racism, and Racial Equity (R3) Symposium, April; 19, 2022
  - Responding to Discrimination and Mistreatment in Clinical Education, February 2, 2022
  - Racial Equity Institute Groundwater Training, April 12-13, 2021
  - Speaking Up: Microaggression Training March 10, 2021
  - Implicit Bias 101 training, February 17, 2021
  - Students in Training, Academia, Health, and Research (STAHR) Mentoring / Leadership Program. August 2020-June 2021
  - Unconscious Bias Awareness Workshop, September 28, 2020
  - Health Care Safe Zone Training September 15, 2020
- Relational Leadership at Carolina, October-November 2020
- Intermountain Healthcare Advanced Training Program in Healthcare Delivery Improvement (accelerated course), Murray, Utah, January-May 2019

- Leadership Development for Physicians in Academic Health Centers, Harvard School of Public Health Center for Continuing Professional Education, Boston, Massachusetts, October 29-November 10, 2017
- American Urological Association Leadership Program, Linthicum, Maryland, July 27-29, 2012

### Grant Review Activities

2021	National Cancer Institute Special Emphasis Panel (SEP) for RFA-CA-20-043—Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01)
2018-2020	Scientific Review Group Member, Bladder Cancer Advocacy Network Patient-Centered Outcomes Research Award
2017-2019	Scientific Review Group Member, Bladder Cancer Advocacy Network Innovation Award
2016-2019	Urology Care Foundation Research Scholars Grant Program
2016	American Urological Association Russell Scott Residency Research Award
2016	American Urological Association Herbert Brendler Summer Medical Student Research Fellowship
2015	Patient-Centered Outcomes Research Institute (PCORI), External reviewer for Large Pragmatic Studies
2013-2016	Scientific Review Group member, Bladder Cancer Advocacy Network Young Investigator Award
2013-2016	Internal reviewer, UNC Lineberger Comprehensive Cancer Center Developmental Award Program
2014	V Foundation for Cancer Research, Ad Hoc External Reviewer
2013	Patient-Centered Outcomes Research Institute (PCORI), External reviewer for Improving Healthcare Systems
2011	External Reviewer, UNC Nutrition Obesity Research Center
2010	External reviewer, South African Medical Research Council
2007	External reviewer, U.S. Civilian Research and Development Foundation Cooperative Grants Program

### Editorial Activities

- Editorial Board Member, *Urologic Oncology: Seminars and Original Investigations*, 2021-present
- Editorial Board Member, *Bladder Cancer*, 2014-present
- Editorial Board Member, *World Journal of Clinical Oncology*, 2015-2018
- Assistant Editor and Editorial Board Member, *Urological Oncology: Seminars and Original Investigations*, 2014-2018
- Associate Editor, Surgical Oncology and Imaging, *BMC Cancer*, 2013-2016
- Editorial Board Member, *Clinical Nephrology and Urology Science*, 2013-2015
- Editorial Board Member, *Advances in Urology*, 2012-2014

*Ad Hoc* Editorial Reviewer:

- JAMA
- *Annals of Internal Medicine*
- *NEJM Catalyst*
- *Campbell-Walsh Textbook of Urology*
- *Cancer*
- *Cancer Epidemiology, Biomarkers & Prevention*
- *Annals of Surgery*
- *Journal of Oncology Practice*
- *Journal of General Internal Medicine*
- *Health Services Research*
- *Epidemiology*
- *Urology*
- *Journal of Urology*
- *European Urology*
- *British Journal of Urology*
- *Clinical Cancer Research*
- *Urologic Oncology: Seminars and Original Investigations*
- *BMC Cancer*
- *Psycho-Oncology*
- *International Journal of Technology Assessment in Health Care*
- *Journal of Surgical Oncology*
- *Cancer Investigation*
- *Journal of Geriatric Oncology*
- *Urology Practice*
- *BMC Medical Informatics and Decision Making*
- *World Journal of Urology*
- *Indian Journal of Urology*
- *Expert Review of Pharmacoeconomics & Outcomes Research*
- *Journal of Andrology*
- *Prostate Cancer and Prostatic Diseases*
- *Advances in Urology*
- *Journal of the National Comprehensive Cancer Network*

**Professional Society Membership**

- Society for Women in Urology, 2021-present
- Association of Women Surgeons, 2018-present
- Health Care Systems Research Network, 2015-present
- American College of Surgeons Surgical Outcomes Club, 2012-present

- Southeastern Section of the American Urological Association, 2012-present
- American College of Surgeons, Associate Fellow, 2009-2012; Fellow 2012-present
- Society of Urologic Oncology, 2011-present
- Society for Medical Decision Making, 2010-present
- International Society for Pharmacoeconomics and Outcomes Research, 2015-2017
- North Carolina Oncology Association, 2010-2012
- American Society of Clinical Oncology, Active Member, 2009-2013
- American Urological Association, 2003-present

## **Reflective Statement**

With exceptional institutional and human resources and a strong tradition of collegial multidisciplinary collaboration, UNC provides the ideal setting for leadership and professional development in academic medicine. I feel incredibly fortunate to have been given the opportunity to begin my career in this context, and this initial experience has only deepened my commitment to the institution and my appreciation of and enthusiasm for the career trajectory made possible by it. During this period, I have established myself as a surgeon-scientist, grown as a leader in my institution and with multiple national and international organizations, developed a strong network of collaborators, mentored junior colleagues, and elaborated a longer-term strategy bringing innovative approaches to bear on important clinical and policy problems.

In the clinical arena, I was fortunate to join a well-established genitourinary oncology group, exceptional among nationally recognized institutions for the degree of seamless multidisciplinary integration. In this supportive environment, I brought the clinical experiences and perspectives from my training at Johns Hopkins Hospital, while benefiting from the expertise of my UNC clinical mentors. Under their guidance, I gained expertise in advanced robotic surgical approaches to urologic cancers, towards the goal of constantly seeking the most innovative and beneficial treatments for patients stricken with these serious conditions. Following our establishment as a Department of Urology in 2013, I was promoted to Director of the Division of Urologic Oncology, serving through 2018. During this period, our Division grew from three to seven faculty, and our Department rose from unranked to top-20 nationally recognized programs in Urology in the US News Ranking (#16 in 2016). I was excited to take on leadership of our Department as Interim Chair in 2020, and was honored to be selected to continue in this role as of November 2020. In my term as Chair, our Department has continued to grow, to 19 physician faculty and 13 advanced practice providers. Our excellence in patient care, teaching, and research have been recognized as the highest-ranking Department at UNC in the US News national rankings year over year.

## **Research Statement**

While balancing the demands associated with establishing a busy practice in urologic oncology, I pursued a broad-based academic career development plan. Immediately upon my arrival at UNC, I sought out mentors with shared interests and complementary expertise and was fortunate to have my application for the institutional KL2 program funded on the first submission in the spring of 2009. This provided me access to the exceptional career development resources of the CTSA-supported Master's in Science, Clinical Research (MSCR) track in the Department of Epidemiology, which I completed in 2012. This comprehensive didactic curriculum fleshed out relevant skill sets for a career in clinical research, building on my strong foundation in outcomes research from residency, while also introducing me to new disciplines and approaches that provided a basis to pursue my longer-term academic goals.

Under the mentorship of Michael Pignone, I was honored to receive funding on the American Cancer Society Mentored Research Scholar Grant, which supported the intermediate-term goals of obtaining additional data and cultivating skills in modeling and medical decision-making research, bridging the disciplines of urologic oncology and decision sciences. The promise of this line of

investigation and mentored career development was recognized by my selection for the Urology Care Foundation / Astellas Rising Stars in Urology Research Award. During this time, I continued to develop additional productive collaborations. First, in work related to the simulation modeling aims of my ACS award, I received Development Award funding from the UNC Lineberger Cancer Center for preliminary work with collaborators from the Erasmus Medical Center in Rotterdam to support future applications for comparative modeling studies in bladder cancer. In addition, a collaboration with investigators in the NCI-funded HMO Cancer Research Network led to a funded R21 application to support development of patient-centered decision support interventions for superficial bladder cancer. My appointment as a Clinical Investigator at the Kaiser Permanente Center for Health Research further bolsters collaborations between the UNC Cancer Outcomes Research Program and the Health Care Systems Research Network (HCSRN). In parallel, I was honored to be invited to serve as a consultant to the American College of Physicians' High Value Care Task Force on the topic area of hematuria evaluation. This work, in turn, led to additional research opportunities at the intersection of simulation modeling, implementation science and quality improvement, for which our group is developing a multi-faceted research agenda. These contributions led to my service on the American Urological Association's Guideline Panel for hematuria evaluation, which dramatically altered recommendations that will impact the care of the over 2 million US patients referred to urologists annually for this condition. Work in the NCI-funded Mentored Training in Dissemination and Implementation Research in Cancer (MT-DIRC) fellowship converged with these interests, laying the groundwork for large-scale pragmatic studies in the HCSRN. Most recently, we have been engaged in work around diagnostic, focusing on opportunities to enhance quality, efficiency, and equity in prostate cancer locally, across North Carolina, and nationally.

I am indebted and thankful to the many mentors who inspired and taught me by their example to pursue a career in academic medicine. My academic interests in implementation science and health services research are animated by the questions and problems that arise in the care of patients in my areas of clinical expertise, specifically, bladder and prostate cancer. My background in clinical epidemiology dovetails with my research interests in hematuria diagnostic evaluation, and my interests in quality improvement and patient safety led to a body of work in opioid stewardship. These areas of scholarly focus led to a variety of applied research and service activities drawing on principles of delivery system science and care redesign. As an academic surgeon, I am motivated to seek the best possible treatment for my patients while seeking to inspire and educate the medical students and residents I work with, as my mentors did for me in those critical early phases of my own career. My vision for the future is to continue to build the expertise and collaborations necessary to establish a nationally recognized multidisciplinary patient-centered research program in medical decision-making and implementation science, intersecting with my contributions to our institutional mission of quality improvement. I believe this vision will contribute substantively to the larger goal of supporting my institution to become the premier public Academic Medical Center nationally.

### **Teaching Statement**

As a clinically active faculty member, I have enjoyed the transition from student to teacher, mentoring residents and medical students on the urology service, and was honored to receive the

Attending of the Year Award from our residents in 2014. I have also had the opportunity to mentor several junior faculty, at our institution and nationally, as well as medical students, residents, and graduate students in the School of Public Health on research projects. I have served as a doctoral dissertation committee member for multiple trainees in the Cancer Care Quality Training Program in the department of Health Policy and Management and Predoctoral trainees in Cancer Epidemiology, departments in which I hold adjunct faculty positions, as well as in the Schools of Medicine and Nursing. As the beneficiary of years of mentorship from established physician scientists, I look forward to expanding my service in this capacity in the years to come, as we recruit additional academically oriented junior faculty members and establish a urologic oncology fellowship in our division. Alongside these local teaching and mentorship activities, I have enjoyed the opportunity to share insights from our scholarly work and quality improvement programs through publications, oral presentations, and workshops with numerous audiences locally, regionally, nationally, and internationally. In recent years, the opportunity to teach an undergraduate Honors seminar on “The Art of Medicine” has provided a unique perspective to reflect on the profession and inspire the next generation.

### **Service and Engagement Statement**

Administratively, I served as the Physician Service Leader for our Department from shortly after my arrival in 2009, working in a close multidisciplinary collaboration with colleagues on our inpatient service and the healthcare system’s Performance Improvement and Patient Safety staff on multiple quality improvement projects. Our group has consistently exceeded organizational goals and national benchmarks for quality, efficiency, and patient experience. In more recent years, I have assumed institutional leadership roles in quality and safety, including ongoing institution-wide efforts to reduce the burden of catheter-associated urinary tract infections and improve the quality of medical documentation across the surgical services, exceeding organizational goals and national benchmarks. In recognition of these efforts, I was honored to receive the UNC Health Care System Friend of Nursing Award in 2017. Over the past several years, I became deeply involved with UNC’s Opioid Stewardship initiative, serving as the physician lead for surgical services and assisting with spread of this work across institutions in our Health Care System. In 2018, I was appointed Associate Director of the UNC Institute for Healthcare Quality Improvement (IHQI) under the mentorship of Darren Dewalt, coaching improvement projects across the institution and leading efforts to develop physician and nurse leaders’ improvement capacity. Completion of the Intermountain Healthcare Advanced Training Program in Healthcare Delivery Improvement supports my contribution in these roles, which naturally dovetail with my research interests and longer-term career goals. Transitioning into the role of Department Chair, I continue to be actively engaged in institutional quality improvement activities, serving as a physician lead for our Health Care System-wide Care Redesign initiative focused on optimizing blood product utilization and as the Clinical Department Chairs’ liaison to the UNC Medical Center Improvement Council. Since 2021, I have served as Director of Quality for UNC Faculty Physicians, during which time our hospital received the Vizient “Rising Star” Award and, for the first time, CMS 5-Star rating. Currently, I am responsible for the Clinical Excellence pillar of our UNC Health Forward Together 2030 strategic plan, coordinating activities across our statewide entities to enable our mission of serving all the people of North Carolina and beyond.

Outside the institution, I served as a member of the Scientific Advisory Board for the Bladder Cancer Advocacy Network, the national bladder cancer patient advocacy group from 2009-2017 and Chair of the BCAN Bladder Cancer Think Tank in 2017. In 2012, I was selected for the American Urological Association Leadership Program and was subsequently appointed to the AUA's Quality Improvement and Patient Safety Committee, which I subsequently served as Chair. I currently serve as Chair of the AUA's Science and Quality Council, providing strategic oversight and leadership across the activities of the AUA's Practice Guidelines, Quality Improvement and Patient Safety, and Data Committees. In 2013, I was appointed to the Physician Consortium for Performance Improvement (PCPI) Outcomes Ad Hoc Committee, and in 2015, I was nominated to represent the Council of Medical Specialty Societies at PCPI, complementing the performance measurement activities at the AUA. In 2018, I was appointed to the Performance Measurement Committee of the American College of Physicians, further informing my work on measure development for the AUA. More recently, I was appointed to multiple Technical Expert Panels with the Centers for Medicare and Medicaid Services. These include the Panel responsible for the Quality Measure Development Plan (MDP) and the Quality Measure Index (QMI), supporting the optimization of the quality measurement enterprise nationally. I serve as UNC's institutional representative to the High Value Practice Alliance (HVPA) and was appointed co-Director of their Cross-institutional Quality Improvement activities in 2018. The work with HVPA provided opportunities to scale our local opioid stewardship work nationally, in partnership with the American Hospital Association. Most recently, I was selected to serve on the National Quality Forum's Diagnostic Excellence Committee and as a Scholar in Diagnostic Excellence with the National Academy of Medicine. Our current work is coordinating efforts across the American Urological Association, the American College of Physicians, and the American College of Radiology to leverage shared interests across the disciplines in advancing the goal of Diagnostic Excellence in general, with a particular focus on opportunities to improve health equity in prostate cancer outcomes for Black men and men in rural communities in the United States.

These national leadership roles, in turn, intersect with opportunities to position UNC at the vanguard of state- and national-level leadership in quality improvement, in partnership with the AUA and other national organizations. I feel incredibly fortunate to have had these opportunities for servant leadership, and look forward to continuing to mentor and sponsor junior colleagues' development both locally and nationally. My diverse portfolio of leadership experience in research, quality improvement, and patient safety informs my role of Urology Department Chair as well as multiple System leadership roles. I am honored to have these opportunities to support and serve the greater good of our institution and organized medicine on the national scale.